ClinicalTrials.gg
Active, not recruitingNCT03504397SpotlightUpdated Oct 20, 2026Results posted

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

A Phase 3 interventional study of zolbetuximab and placebo in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer and Metastatic Gastric Adenocarcinoma or Cancer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 218 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Updated Oct 20, 2026Study completion moved2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
565
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Adenocarcinoma by Astellas Pharma Inc — 7 open to participants now, 9 under way, 4 of them phase 3. Adenocarcinoma · Astellas Pharma Inc.

Started
2018
with 1 other
Phase 3
4 of 12
2 open now
Registered
2nd of 12
by date

Among the 12 studies in Adenocarcinoma by Astellas Pharma Inc, this one is one of 2 that started in 2018, is one of 4 in phase 3, and was the 2nd registered.

Adenocarcinoma

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

7 of the 12 studies in Adenocarcinoma by Astellas Pharma Inc are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 111 Adenocarcinoma studies recruiting now, 82 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Adenocarcinoma by Astellas Pharma Inc, or all of them as a file.
02

Study summary

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ cancer will either be given zolbetuximab with chemotherapy or a placebo with chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. Zolbetuximab with chemotherapy has already been approved to treat gastric cancer and GEJ cancer in some countries. This study is being done in countries where zolbetuximab has not yet been approved for use. If zolbetuximab becomes approved for use in those countries taking part in this study, the study doctor will switch study treatment in those countries to the licensed zolbetuximab. If this happens, people taking part in those countries will leave this study and receive licensed zolbetuximab.

The main aim of the study is to check if zolbetuximab and chemotherapy can prevent or delay the worsening of people's gastric cancer and GEJ cancer compared to placebo and chemotherapy.

Adults with advanced stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample of their cancer will also have the Claudin 18.2 protein. They may have been previously treated with certain standard therapies, but have not been treated with chemotherapy for their cancer. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections.

The study treatments are either zolbetuximab with chemotherapy, or placebo with chemotherapy. People who take part will receive just 1 of the study treatments by chance. Study treatment will be double-blinded. That means that the people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in cycles. The study treatment is given to people slowly through a tube into a vein. This is called an infusion. People will have 4 infusions in 6-week (42-day) cycles as follows:

  • Zolbetuximab or placebo - 2 infusions in a cycle.
  • Chemotherapy (called modified FOLFOX6 or mFOLFOX6) - 3 infusions in a cycle. The first infusion is combined with zolbetuximab or placebo on day 1 of each cycle. People may receive zolbetuximab or placebo until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will receive mFOLFOX6 for up to 6 months (4 study treatment cycles). After the 6 months people may receive chemotherapy containing folinic acid and fluorouracil instead of mFOLFOX6. People may receive folinic acid and fluorouracil chemotherapy for more than 6 months, or until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People will visit the clinic on certain days during their study treatment. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. Also, people in the study will have health checks. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample after their study treatment has finished. People will visit the clinic after they stop their study treatment. People who start treatment with licensed zolbetuximab or mFOLFOX6 outside of this study will not need to visit the clinic. People will be asked about any medical problems and will have a health check. People will visit the clinic at 1 month after they stop their study treatment. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. People will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.
Read the detailed description

After the marketing approval in Japan on 26 Mar 2024, this study continued as "post marketing clinical study" in Japan. In the rest of the countries which participated in this study, this study continued as clinical study.

03

Conditions studied

  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
  • Metastatic Gastric Adenocarcinoma or Cancer
  • Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Keywords

  • HER2
  • IMAB362
  • leucovorin
  • fluorouracil
  • Gastric cancer
  • claudiximab
  • zolbetuximab
  • oxaliplatin
  • adenocarcinoma
  • Gastro-Esophageal Junction cancer
  • HER2 Negative mFOLFOX6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subject eligible to participate if she is not pregnant (negative serum pregnancy test at screening; female subjects with elevated serum beta human chorionic gonadotropin and a demonstrated non-pregnant status through additional testing are eligible) and at least one of the following conditions applies:

    • Not a woman of (WOCBP) OR
    • WOCBP who agrees to follow the guidance throughout the treatment period and for at least 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study drugs.
  • A sexually active male subject with a female partner(s) who is of child-bearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.
  • Male subject must agree not to donate sperm starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.
  • Subject has confirmed diagnosis of Gastric or GEJ adenocarcinoma.
  • Subject has radiologically confirmed locally advanced unresectable or disease within 28 days prior to randomization.
  • Subject has radiologically evaluable disease (measurable and/or non- according to 1.1), per local assessment, ≤ 28 days prior to randomization. For subjects with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before randomization, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy.
  • Subject's tumor expresses CLDN18.2 in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central immunohistochemistry (IHC) testing.
  • Subject has a -Negative tumor as determined by local or central testing on a gastric or GEJ tumor specimen. (Unique to China: Subject has a known HER2-negative gastric or GEJ tumor.)
  • Subject has performance status 0 to 1.
  • Subject has predicted ≥ 12 weeks.
  • Subject must meet all of the following criteria based on the centrally or locally analyzed laboratory tests collected within 14 days prior to randomization. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility.

    • (Hgb) ≥ 9 g/dL. Subjects requiring transfusions are eligible if they have a post-transfusion Hgb ≥ 9 g/dL.
    • (ANC) ≥ 1.5 x 10\^9/L
    • ≥ 100 x 10\^9/L
    • Albumin ≥ 2.5 g/dL
    • Total ≤ 1.5 x (ULN) without liver metastases (or \< 3.0 x ULN if liver metastases are present)
    • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN without liver metastases (or ≤ 5 x ULN if liver metastases are present)
    • Estimated ≥ 30 mL/min
    • (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) ≤ 1.5 x ULN (except for subjects receiving anticoagulation therapy)

Exclusion criteria

Exclusion Criteria:

  • Subject has received prior systemic chemotherapy for locally advanced unresectable or gastric or GEJ adenocarcinoma. However, subject may have received either or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies, as long as it was completed at least 6 months prior to randomization. Subject may have received treatment with herbal medications that have known antitumor activity > 28 days prior to randomization.
  • Subject has received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to randomization and has not recovered from any related toxicity.
  • Subject has received systemic therapy, including systemic within 14 days prior to randomization. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use are allowed.
  • Subject has received other agents or devices within 28 days prior to randomization.
  • Subject has prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.
  • Subject has known immediate or delayed , intolerance or to any component of study treatment.
  • Subject has prior severe allergic reaction or intolerance to any component of mFOLFOX6.
  • Subject has known dihydropyrimidine dehydrogenase deficiency.
  • Subject has a complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
  • Subject has significant gastric bleeding and/or untreated gastric ulcers that would exclude the subject from participation.
  • Subject has a known history of a positive test for (HIV) infection or known active (positive hepatitis B surface antigen (HBs Ag)) or C infection. NOTE: Screening for these infections should be conducted per local requirements.

    • For subjects who are negative for HBs Ag, but hepatitis B core antibody (HBc Ab) positive, an HB deoxyribonucleic acid (DNA) test will be performed and if positive, the subject will be excluded.
    • Subjects with positive virus (HCV) serology, but negative HCV ribonucleic acid (RNA) test are eligible.
    • Subjects treated for HCV with undetectable viral load results are eligible.
  • Subject has an active disease that has required systemic treatment within the past 3 months prior to randomization.
  • Subject has active infection requiring systemic therapy that has not completely resolved within 7 days prior to randomization.
  • Subject has significant cardiovascular disease, including any of the following:

    • Congestive heart failure (defined as Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, stenting, coronary artery bypass graft, cerebrovascular accident (CVA) or hypertensive crisis within 6 months prior to randomization.
    • History of ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes)
    • > 450 msec for male subjects; QTc interval > 470 msec for female subjects
    • History or family history of congenital long QT syndrome
    • Cardiac arrhythmias requiring anti-arrhythmic medications (Subject with rate controlled atrial fibrillation for > 1 month prior to randomization are eligible).
  • Subject has a history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer.
  • Subject has known peripheral sensory neuropathy > Grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality.
  • Subject has had a major surgical procedure ≤ 28 days prior to randomization.

    • Subject is without complete recovery from a major surgical procedure ≤ 14 days prior to randomization.
  • Subject has psychiatric illness or social situations that would preclude study compliance.
  • Subject has another for which treatment is required.
  • Subject has any concurrent disease, infection or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
565 participants (actual)

Study arms

  • Experimental
    mFOLFOX6 + Zolbetuximab

    Participants received intravenous (IV) infusion (minimum 2-hour) of zolbetuximab at a loading dose of 800 milligrams per square meter (mg/m\^2) on cycle1 day1(C1D1) followed by 600 mg/m\^2 every 3 weeks starting from C1D22 until study treatment discontinuation criteria were met. Participants also received upto 12 treatments of mFOLFOX6 (or components if some were discontinued due to toxicity) over 4/more cycles. mFOLFOX6 was administered on Days 1, 15 \& 29 of each cycle (5-FU:400mg/m\^2 IV bolus over 5-15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid: 400mg/m\^2 IV infusion over 2 hours; oxaliplatin: 85mg/m\^2 IV infusion over 2 hours) A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants continued to receive 5-FU \& Folinic acid on Days 1, 15 \& 29 of each cycle at the investigator discretion or until study treatment discontinuation criteria were met. Each cycle was approximately 42 days.

    Drug: zolbetuximab · Drug: oxaliplatin · Drug: folinic acid · Drug: fluorouracil

  • Placebo comparator
    Placebo plus mFOLFOX6

    Participants received an IV infusion (minimum 2-hour infusion) of placebo matched to zolbetuximab on C1D1, followed by subsequent doses every 3 weeks starting from C1D22 until study treatment discontinuation criteria were met. Participants also received up to 12 treatments of mFOLFOX6 (or components if some were discontinued due to toxicity) over 4 or more cycles. mFOLFOX6 was administered on Days 1, 15, and 29 of each cycle (5-fluorouracil: 400 mg/m\^2 IV bolus over 5-15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Folinic acid: 400 mg/m\^2 IV infusion over 2 hours; oxaliplatin: 85 mg/m\^2 IV infusion over 2 hours). A maximum of 12 doses of oxaliplatin was permitted. After mFOLFOX6 treatments, participants could continue to receive 5-FU and folinic acid on Days 1, 15, and 29 of each cycle at the investigator's discretion or until study treatment discontinuation criteria were met. Each cycle was approximately 42 days.

    Drug: placebo · Drug: oxaliplatin · Drug: folinic acid · Drug: fluorouracil

Interventions

  • Participants received an IV infusion (as a minimum of 2-hour infusion) of zolbetuximab at a loading dose of 800 mg/m\^2 on C1D1 followed by subsequent doses of 600 mg/m\^2 every 3 weeks starting from C1D22 until participant meets study treatment discontinuation criteria. Each cycle was approximately 42 days.

    Also known as: IMAB362

  • Drugplacebo

    Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.

  • Participants received up to 12 treatments of oxaliplatin administered 85 mg/m\^2 IV infusion over 2 hours) on Days 1, 15 and 29 of each cycle.. A maximum of 12 doses of oxaliplatin was permitted. Each cycle was approximately 42 days.

  • Participants received up to 12 treatments of folinic acid administered 400 mg/m\^2 IV infusion over 2 hours 4 or more cycles on Days 1, 15 and 29 of each cycle. participants could continue to receive folinic acid on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.

  • Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan -Meier (KM) estimates was used.

    Time frame: From date of randomization until the date of first documented radiological progression or date of death from any cause, whichever occurred first (up to 62 months and 18 days)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.

    Time frame: From the date of randomization until 62 months and 18 days

  2. Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)

    TTCD: time from randomization to first clinically meaning full deterioration (CMD) that was confirmed at next scheduled visit. EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical,role,emotional,social \& cognitive), 9 symptom scales (fatigue, nausea/vomiting,general pain,dyspnea,insomnia,appetite loss,constipation,diarrhea,financial difficulties) \& global health status scale. Most items were scored 1(not at all) to 4(very much) except for items contributing to global health status/QoL, which were scored 1(very poor) to 7(excellent). All raw domain scores were linearly transformed to 0-100scale with higher scores on symptoms indicate worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -13. This was derived from an Exit Survey conducted using Patient Global Impression of Severity/Change(PGIS/PGIC) questionnaires as an anchor for estimating meaningful change. KM estimates was used.

    Time frame: From the date of randomization until 62 months and 18 days

  3. Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25

    TTCD: time from randomization to first CMD that was confirmed at next scheduled visit. EORTC QLQ-OG25 evaluated gastric and GEJ cancer specific symptoms. A 25 item instrument with 6 scales: dysphagia (3 items), eating restrictions (4 ), reflux (2), odynophagia (2), pain and discomfort (2), anxiety (2), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight and hair loss. Items were scored:1: not at all; 2: a little, 3: quite a bit, 4: very much, and were transformed linearly into scores (0 to 100) with higher scores indicating worse symptoms. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of 16.67. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.

    Time frame: From the date of randomization until 62 months and 18 days

  4. Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30

    TTCD: time from randomization to first CMD that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items were scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which were scored 1 ("very poor") to 7 ("excellent"). All raw domain scores were linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -10. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.

    Time frame: From the date of randomization until 62 months and 18 days

  5. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.

    Time frame: From the date of randomization until 62 months and 18 days

  6. Duration Of Response (DOR)

    DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.PD was defined as development of new, or progression of existing metastases to the primary cancer under the sudy.

    Time frame: From date of first response (CR/PR) until 62 months and 18 day

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or notconsidered related to the medicinal product. TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.

    Time frame: From first dose until 62 months and 18 days

  8. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

    ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

    Time frame: Baseline, cycle (C) 1 day (D) 22, D1 and D22 of C2 through C39

  9. Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire

    The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.

    Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up

  10. Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire

    The EORTC-QLQ-OG25 consists of a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All questions have four response alternatives (1:not at all; 2:a little, 3:quite a bit, 4:very much). Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 For symptom scales/items, higher scores indicate worse symptoms.

    Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up

  11. Change From Baseline in HRQoL Measured by Global Pain (GP)

    The GP instrument is a single assessment of overall pain. Participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain.

    Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up

  12. Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire

    EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

    Time frame: Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up

  13. Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)

    Ctrough was defined as the predose concentration at the end of dosing interval.

    Time frame: Predose on C1D22, C3D1, C5D1, C7D1, C9D1

  14. Number of Participants With Anti-drug Antibodies (ADA)

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Predose on C1D1, C1D22, C3D1, C5D1, C7D1, C9D1, 30-day follow up, 90-day follow up

07

Results

Posted Feb 26, 2025

Participant flow

Participants with claudin (CLDN)18.2-positive, human epidermal growth factor receptor 2 (HER2) -negative locally advanced unresectable or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Participant flow — Overall Study
MilestonemFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Started283282
Participants who received at least one dose of study drug279278
Completed2617
Not completed257265
Withdrew: Progressive disease151199
Withdrew: Withdrawal by subject2917
Withdrew: Lost to follow-up10
Withdrew: Death1416
Withdrew: Adverse event4014
Withdrew: Miscellaneous1715
Withdrew: Protocol deviation10
Withdrew: Participants who did not take the study drug44

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of radiological progressive disease (PD) (per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 by independent review committee \[IRC\]) or death from any cause, whichever was earliest. PD was defined as development of new, or progression of existing metastases to the primary cancer under the study. Kaplan -Meier (KM) estimates was used.

Time frame:
From date of randomization until the date of first documented radiological progression or date of death from any cause, whichever occurred first (up to 62 months and 18 days)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Progression Free Survival (PFS)11.04 (9.69 to 12.52)8.94 (8.21 to 10.41)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Log Rank · p = 0.0024 (Log-rank test stratified by: * Region (Asia vs Non-Asia) * Number of organs with metastatic sites (0 to 2 vs ≥ 3) * Prior gastrectomy (Yes or No)) · Hazard ratio (hr): 0.734 · 95% CI 0.591 to 0.910
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause. Kaplan-Meier estimates was used.

Time frame:
From the date of randomization until 62 months and 18 days
Reported as:
Median · Months
Overall Survival (OS)
MonthsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Overall Survival (OS)18.23 (16.13 to 20.63)15.57 (13.67 to 16.92)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Log Rank · p = 0.0075 (Log-rank test stratified by: * Region (Asia vs Non-Asia) * Number of organs with metastatic sites (0 to 2 vs ≥ 3) * Prior gastrectomy (Yes or No)) · Hazard ratio (hr): 0.784 · 95% CI 0.644 to 0.954
SecondaryTime to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)

TTCD: time from randomization to first clinically meaning full deterioration (CMD) that was confirmed at next scheduled visit. EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical,role,emotional,social \& cognitive), 9 symptom scales (fatigue, nausea/vomiting,general pain,dyspnea,insomnia,appetite loss,constipation,diarrhea,financial difficulties) \& global health status scale. Most items were scored 1(not at all) to 4(very much) except for items contributing to global health status/QoL, which were scored 1(very poor) to 7(excellent). All raw domain scores were linearly transformed to 0-100scale with higher scores on symptoms indicate worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -13. This was derived from an Exit Survey conducted using Patient Global Impression of Severity/Change(PGIS/PGIC) questionnaires as an anchor for estimating meaningful change. KM estimates was used.

Time frame:
From the date of randomization until 62 months and 18 days
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)
MonthsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Time to Confirmed Deterioration (TTCD) Using Physical Functioning (PF) as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)9.89 (6.01 to NA)12.32 (9.26 to NA)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Log Rank · p = 0.0280 (Log-rank test stratified by: * Region (Asia vs Non-Asia) * Number of organs with metastatic sites (0 to 2 vs ≥ 3) * Prior gastrectomy (Yes or No)) · Hazard ratio (hr): 1.295 · 95% CI 0.994 to 1.687
SecondaryTime to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25

TTCD: time from randomization to first CMD that was confirmed at next scheduled visit. EORTC QLQ-OG25 evaluated gastric and GEJ cancer specific symptoms. A 25 item instrument with 6 scales: dysphagia (3 items), eating restrictions (4 ), reflux (2), odynophagia (2), pain and discomfort (2), anxiety (2), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight and hair loss. Items were scored:1: not at all; 2: a little, 3: quite a bit, 4: very much, and were transformed linearly into scores (0 to 100) with higher scores indicating worse symptoms. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of 16.67. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.

Time frame:
From the date of randomization until 62 months and 18 days
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25
MonthsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Time to Confirmed Deterioration (TTCD) Using Oesophago-gastric Questionnaire (OG25) on Abdominal Pain and Discomfort as Measured by EORTC QLQ-OG25NA (NA to NA)NA (15.67 to NA)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Log Rank · p = 0.0508 (Log-rank test stratified by: * Region (Asia vs Non-Asia) * Number of organs with metastatic sites (0 to 2 vs ≥ 3) * Prior gastrectomy (Yes or No)) · Hazard ratio (hr): 0.713 · 95% CI 0.475 to 1.071
SecondaryTime to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30

TTCD: time from randomization to first CMD that was confirmed at the next scheduled visit. The EORTC-QLQ-C30 was a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items were scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which were scored 1 ("very poor") to 7 ("excellent"). All raw domain scores were linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state. CMD was defined if a participant's change from baseline exceeded a pre-specified threshold of -10. This was derived from an Exit Survey conducted to use PGIS/PGIC questionnaires as an anchor for estimating the meaningful change. KM estimates was used.

Time frame:
From the date of randomization until 62 months and 18 days
Reported as:
Median · Months
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C30
MonthsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Time to Confirmed Deterioration (TTCD) Using Global Health Status as Measured by EORTC QLQ-C3015.44 (7.06 to 23.89)11.83 (9.23 to 15.08)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Log Rank · p = 0.1685 · Hazard ratio (hr): 1.142 · 95% CI 0.874 to 1.492Log-rank test stratified by: * Region (Asia vs Non-Asia) * Number of organs with metastatic sites (0 to 2 vs ≥ 3) * Prior gastrectomy (Yes or No)
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as was assessed by IRC per RECIST 1.1. CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.

Time frame:
From the date of randomization until 62 months and 18 days
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Objective Response Rate (ORR)48.1 (42.11 to 54.05)47.5 (41.56 to 53.52)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Cochran-Mantel-Haenszel · p = 0.4536Based on 1-sided Cochran-Mantel-Haenszel (CMH) test. Stratification factors were Region, Number of Metastatic Sites and Prior Gastrectomy.
SecondaryDuration Of Response (DOR)

DOR was defined as the time from the date of the first response (CR/PR) until the date of PD as assessed by IRC per RECIST 1.1 or date of death from any cause, whichever is earliest.CR was defined as complete resolution of all attributable clinical symptoms and physical findings. PR was defined as partial resolution of at Least some of the clinical symptoms and physical findings.PD was defined as development of new, or progression of existing metastases to the primary cancer under the sudy.

Time frame:
From date of first response (CR/PR) until 62 months and 18 day
Reported as:
Median · Months
Duration Of Response (DOR)
MonthsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Duration Of Response (DOR)9.00 (7.49 to 10.38)8.11 (6.47 to 11.37)
Statistical analysis
  • mFOLFOX6 + Zolbetuximab vs mFOLFOX6+ Placebo · Log Rank · p = 0.0721 · Hazard ratio (hr): 0.789 · 95% CI 0.573 to 1.087Log-rank test stratified by: * Region (Asia vs Non-Asia) * Number of organs with metastatic sites (0 to 2 vs ≥ 3) * Prior gastrectomy (Yes or No)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An Adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or notconsidered related to the medicinal product. TEAE defined as an AE observed after starting administration of the study drug through 30 days after the last dose.

Time frame:
From first dose until 62 months and 18 days
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Number of Participants With Treatment Emergent Adverse Events (TEAEs)278277
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.

Time frame:
Baseline, cycle (C) 1 day (D) 22, D1 and D22 of C2 through C39
Reported as:
Number · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsmFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Baseline Score 0125115
Baseline Score 1153163
Baseline Score 210
Baseline Score 300
Baseline Score 400
Baseline Score 500
C1D22 Score 083102
C1D22 Score 1116133
C1D22 Score 283
C1D22 Score 320
C1D22 Score 400
C1D22 Score 500
C2D1 Score 0103112
C2D1 Score 1127144
C2D1 Score 286
C2D1 Score 310
C2D1 Score 400
C2D1 Score 500
C2D22 Score 06478
C2D22 Score 1113123
C2D22 Score 220
C2D22 Score 300
C2D22 Score 400
C2D22 Score 500
C3D1 Score 09491
C3D1 Score 1118132
C3D1 Score 2103
C3D1 Score 300
C3D1 Score 400
C3D1 Score 500
C3D22 Score 07865
C3D22 Score 197104
C3D22 Score 243
C3D22 Score 300
C3D22 Score 400
C3D22 Score 500
C4D1 Score 07879
C4D1 Score 1118115
C4D1 Score 255
C4D1 Score 300
C4D1 Score 400
C4D1 Score 500
C4D22 Score 04954
C4D22 Score 18489
C4D22 Score 263
C4D22 Score 301
C4D22 Score 400
C4D22 Score 500
C5D1 Score 07070
C5D1 Score 1101101
C5D1 Score 281
C5D1 Score 301
C5D1 Score 400
C5D1 Score 500
C5D22 Score 05753
C5D22 Score 16782
C5D22 Score 251
C5D22 Score 300
C5D22 Score 400
C5D22 Score 500
C6D1 Score 06657
C6D1 Score 18284
C6D1 Score 233
C6D1 Score 310
C6D1 Score 400
C6D1 Score 500
C6D22 Score 05150
C6D22 Score 16759
C6D22 Score 231
C6D22 Score 300
C6D22 Score 400
C6D22 Score 500
C7D1 Score 06555
C7D1 Score 17058
C7D1 Score 230
C7D1 Score 310
C7D1 Score 400
C7D1 Score 500
C7D22 Score 04645
C7D22 Score 15645
C7D22 Score 230
C7D22 Score 300
C7D22 Score 400
C7D22 Score 500
C8D1 Score 05352
C8D1 Score 16246
C8D1 Score 220
C8D1 Score 300
C8D1 Score 400
C8D1 Score 500
C8D22 Score 03743
C8D22 Score 14735
C8D22 Score 230
C8D22 Score 300
C8D22 Score 400
C8D22 Score 500
C9D1 Score 04540
C9D1 Score 14834
C9D1 Score 240
C9D1 Score 300
C9D1 Score 400
C9D1 Score 500
C9D22 Score 03337
C9D22 Score 14228
C9D22 Score 210
C9D22 Score 300
C9D22 Score 400
C9D22 Score 500
C10D1 Score 04034
C10D1 Score 14129
C10D1 Score 210
C10D1 Score 300
C10D1 Score 400
C10D1 Score 500
C10D22 Score 02925
C10D22 Score 13823
C10D22 Score 200
C10D22 Score 300
C10D22 Score 400
C10D22 Score 500
C11D1 Score 03623
C11D1 Score 13929
C11D1 Score 220
C11D1 Score 300
C11D1 Score 400
C11D1 Score 500
C11D22 Score 02622
C11D22 Score 13517
C11D22 Score 200
C11D22 Score 300
C11D22 Score 400
C11D22 Score 500
C12D1 Score 02827
C12D1 Score 13719
C12D1 Score 221
C12D1 Score 300
C12D1 Score 400
C12D1 Score 500
C12D22 Score 02417
C12D22 Score 12516
C12D22 Score 210
C12D22 Score 300
C12D22 Score 400
C12D22 Score 500
C13D1 Score 02622
C13D1 Score 13417
C13D1 Score 210
C13D1 Score 300
C13D1 Score 400
C13D1 Score 500
C13D22 Score 02314
C13D22 Score 12912
C13D22 Score 210
C13D22 Score 300
C13D22 Score 400
C13D22 Score 500
C14D1 Score 02318
C14D1 Score 12417
C14D1 Score 201
C14D1 Score 300
C14D1 Score 400
C14D1 Score 500
C14D22 Score 01812
C14D22 Score 11910
C14D22 Score 210
C14D22 Score 300
C14D22 Score 400
C14D22 Score 500
C15D1 Score 01915
C15D1 Score 12415
C15D1 Score 200
C15D1 Score 300
C15D1 Score 400
C15D1 Score 500
C15D22 Score 01512
C15D22 Score 1218
C15D22 Score 200
C15D22 Score 300
C15D22 Score 400
C15D22 Score 500
C16D1 Score 02013
C16D1 Score 12112
C16D1 Score 200
C16D1 Score 300
C16D1 Score 400
C16D1 Score 500
C16D22 Score 0149
C16D22 Score 1187
C16D22 Score 200
C16D22 Score 300
C16D22 Score 400
C16D22 Score 500
C17D1 Score 01510
C17D1 Score 1189
C17D1 Score 210
C17D1 Score 300
C17D1 Score 400
C17D1 Score 500
C17D22 Score 095
C17D22 Score 1134
C17D22 Score 210
C17D22 Score 300
C17D22 Score 400
C17D22 Score 500
C18D1 Score 0138
C18D1 Score 1179
C18D1 Score 200
C18D1 Score 300
C18D1 Score 400
C18D1 Score 500
C18D22 Score 0116
C18D22 Score 1105
C18D22 Score 210
C18D22 Score 300
C18D22 Score 400
C18D22 Score 500
C19D1 Score 098
C19D1 Score 1177
C19D1 Score 201
C19D1 Score 300
C19D1 Score 400
C19D1 Score 500
C19D22 Score 096
C19D22 Score 1126
C19D22 Score 200
C19D22 Score 300
C19D22 Score 400
C19D22 Score 500
C20D1 Score 098
C20D1 Score 1168
C20D1 Score 210
C20D1 Score 300
C20D1 Score 400
C20D1 Score 500
C20D22 Score 077
C20D22 Score 1114
C20D22 Score 210
C20D22 Score 300
C20D22 Score 400
C20D22 Score 500
C21D1 Score 089
C21D1 Score 1147
C21D1 Score 210
C21D1 Score 300
C21D1 Score 400
C21D1 Score 500
C21D22 Score 045
C21D22 Score 1104
C21D22 Score 210
C21D22 Score 300
C21D22 Score 400
C21D22 Score 500
C22D1 Score 064
C22D1 Score 1109
C22D1 Score 210
C22D1 Score 300
C22D1 Score 400
C22D1 Score 500
C22D22 Score 035
C22D22 Score 174
C22D22 Score 210
C22D22 Score 300
C22D22 Score 400
C22D22 Score 500
C23D1 Score 055
C23D1 Score 1108
C23D1 Score 210
C23D1 Score 300
C23D1 Score 400
C23D1 Score 500
C23D22 Score 043
C23D22 Score 194
C23D22 Score 210
C23D22 Score 300
C23D22 Score 400
C23D22 Score 500
C24D1 Score 064
C24D1 Score 1106
C24D1 Score 200
C24D1 Score 300
C24D1 Score 400
C24D1 Score 500
C24D22 Score 023
C24D22 Score 173
C24D22 Score 200
C24D22 Score 300
C24D22 Score 400
C24D22 Score 500
C25D1 Score 043
C25D1 Score 1105
C25D1 Score 200
C25D1 Score 300
C25D1 Score 400
C25D1 Score 500
C25D22 Score 022
C25D22 Score 194
C25D22 Score 200
C25D22 Score 300
C25D22 Score 400
C25D22 Score 500
C26D1 Score 032
C26D1 Score 1104
C26D1 Score 200
C26D1 Score 300
C26D1 Score 400
C26D1 Score 500
C26D22 Score 020
C26D22 Score 163
C26D22 Score 200
C26D22 Score 300
C26D22 Score 400
C26D22 Score 500
C27D1 Score 032
C27D1 Score 1104
C27D1 Score 200
C27D1 Score 300
C27D1 Score 400
C27D1 Score 500
C27D22 Score 021
C27D22 Score 173
C27D22 Score 200
C27D22 Score 300
C27D22 Score 400
C27D22 Score 500
C28D1 Score 042
C28D1 Score 194
C28D1 Score 200
C28D1 Score 300
C28D1 Score 400
C28D1 Score 500
C28D22 Score 020
C28D22 Score 171
C28D22 Score 200
C28D22 Score 300
C28D22 Score 400
C28D22 Score 500
C29D1 Score 042
C29D1 Score 163
C29D1 Score 200
C29D1 Score 300
C29D1 Score 400
C29D1 Score 500
C29D22 Score 021
C29D22 Score 152
C29D22 Score 200
C29D22 Score 300
C29D22 Score 400
C29D22 Score 500
C30D1 Score 032
C30D1 Score 173
C30D1 Score 200
C30D1 Score 300
C30D1 Score 400
C30D1 Score 500
C30D22 Score 01—
C30D22 Score 16—
C30D22 Score 20—
C30D22 Score 30—
C30D22 Score 40—
C30D22 Score 50—
C31D1 Score 032
C31D1 Score 152
C31D1 Score 200
C31D1 Score 300
C31D1 Score 400
C31D1 Score 500
C31D22 Score 011
C31D22 Score 140
C31D22 Score 200
C31D22 Score 300
C31D22 Score 400
C31D22 Score 500
C32D1 Score 010
C32D1 Score 152
C32D1 Score 200
C32D1 Score 300
C32D1 Score 400
C32D1 Score 500
C32D22 Score 01—
C32D22 Score 14—
C32D22 Score 20—
C32D22 Score 30—
C32D22 Score 40—
C32D22 Score 50—
C33D1 Score 011
C33D1 Score 131
C33D1 Score 200
C33D1 Score 300
C33D1 Score 400
C33D1 Score 500
C33D22 Score 01—
C33D22 Score 12—
C33D22 Score 20—
C33D22 Score 30—
C33D22 Score 40—
C33D22 Score 50—
C34D1 Score 011
C34D1 Score 121
C34D1 Score 200
C34D1 Score 300
C34D1 Score 400
C34D1 Score 500
C34D22 Score 01—
C34D22 Score 11—
C34D22 Score 20—
C34D22 Score 30—
C34D22 Score 40—
C34D22 Score 50—
C35D1 Score 000
C35D1 Score 121
C35D1 Score 200
C35D1 Score 300
C35D1 Score 400
C35D1 Score 500
C35D22 Score 000
C35D22 Score 111
C35D22 Score 200
C35D22 Score 300
C35D22 Score 400
C35D22 Score 500
C36D1 Score 000
C36D1 Score 121
C36D1 Score 200
C36D1 Score 300
C36D1 Score 400
C36D1 Score 500
C36D22 Score 000
C36D22 Score 111
C36D22 Score 200
C36D22 Score 300
C36D22 Score 400
C36D22 Score 500
C37D1 Score 00—
C37D1 Score 12—
C37D1 Score 20—
C37D1 Score 30—
C37D1 Score 40—
C37D1 Score 50—
C37D22 Score 00—
C37D22 Score 11—
C37D22 Score 20—
C37D22 Score 30—
C37D22 Score 40—
C37D22 Score 50—
C38D1 Score 00—
C38D1 Score 11—
C38D1 Score 20—
C38D1 Score 30—
C38D1 Score 40—
C38D1 Score 50—
C38D22 Score 00—
C38D22 Score 11—
C38D22 Score 20—
C38D22 Score 30—
C38D22 Score 40—
C38D22 Score 50—
C39D1 Score 00—
C39D1 Score 11—
C39D1 Score 20—
C39D1 Score 30—
C39D1 Score 40—
C39D1 Score 50—
C39D22 Score 00—
C39D22 Score 11—
C39D22 Score 20—
C39D22 Score 30—
C39D22 Score 40—
C39D22 Score 50—
SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire

The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales/items (fatigue, nausea/vomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the global health status/QoL, which are scored 1 ("very poor") to 7 ("excellent"). All raw domain scores are linearly transformed to a 0-100 scale with higher scores on symptoms indicate a worse health state.

Time frame:
Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Reported as:
Mean · units on Scale
Change From Baseline in Health Related Quality of Life (HRQoL) Measured by the EORTC-QLQ-C30 Questionnaire
units on ScalemFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Global Health Status Baseline64.20 ± 20.8663.47 ± 20.63
Global Health Status C1D22-5.18 ± 20.750.48 ± 17.98
Global Health Status C2D11.61 ± 20.405.56 ± 18.68
Global Health Status C2D220.17 ± 18.511.98 ± 20.79
Global Health Status C3D12.85 ± 17.895.77 ± 19.92
Global Health Status C3D22-3.13 ± 19.103.13 ± 18.03
Global Health Status C4D10.64 ± 20.496.65 ± 21.04
Global Health Status C4D22-2.78 ± 18.161.50 ± 22.37
Global Health Status C5D1-0.62 ± 20.694.83 ± 20.71
Global Health Status C5D220.53 ± 21.240.07 ± 21.52
Global Health Status C6D11.90 ± 20.660.07 ± 21.57
Global Health Status C6D223.48 ± 18.212.39 ± 18.15
Global Health Status C7D10.00 ± 20.504.34 ± 17.64
Global Health Status C7D221.54 ± 18.503.38 ± 20.32
Global Health Status C8D13.12 ± 19.824.82 ± 17.90
Global Health Status C8D221.62 ± 19.916.92 ± 18.67
Global Health Status C9D16.11 ± 18.094.57 ± 15.14
Global Health Status C9D223.33 ± 19.543.18 ± 17.82
Global Health Status C10D13.03 ± 18.873.87 ± 19.20
Global Health Status C10D220.58 ± 19.475.43 ± 17.34
Global Health Status C11D14.37 ± 16.923.99 ± 15.09
Global Health Status C11D222.65 ± 18.311.34 ± 16.12
Global Health Status C12D11.89 ± 18.822.64 ± 14.00
Global Health Status C12D22-0.88 ± 17.41-3.33 ± 12.50
Global Health Status C13D13.47 ± 18.180.95 ± 13.52
Global Health Status C13D22-2.85 ± 19.24-0.79 ± 13.15
Global Health Status C14D1-0.85 ± 23.480.83 ± 20.22
Global Health Status C14D22-1.30 ± 19.64-1.32 ± 16.26
Global Health Status C15D1-0.71 ± 26.690.93 ± 16.88
Global Health Status C15D22-3.89 ± 22.92-3.43 ± 18.18
Global Health Status C16D11.90 ± 20.321.89 ± 18.17
Global Health Status C16D22-2.59 ± 20.18-2.38 ± 14.41
Global Health Status C17D1-3.89 ± 28.680.93 ± 13.06
Global Health Status C17D22-6.88 ± 25.33—
Global Health Status C18D10.00 ± 24.57-1.56 ± 13.68
Global Health Status C18D22-7.14 ± 21.94-1.67 ± 12.30
Global Health Status C19D1-3.62 ± 24.60-6.11 ± 14.25
Global Health Status C19D22-4.58 ± 20.32-7.58 ± 12.05
Global Health Status C20D1-2.54 ± 24.671.11 ± 12.94
Global Health Status C20D22-3.70 ± 22.18-0.83 ± 15.93
Global Health Status C21D12.08 ± 20.75-1.79 ± 15.39
Global Health Status C21D22-4.17 ± 17.83—
Global Health Status C22D1-0.56 ± 24.29-6.25 ± 14.70
Global Health Status C22D22-10.61 ± 29.13—
Global Health Status C23D1-4.17 ± 29.03-0.64 ± 15.39
Global Health Status C23D22-3.79 ± 22.16—
Global Health Status C24D1-0.60 ± 26.04—
Global Health Status C25D1-6.94 ± 15.82—
Global Health Status C25D22-3.03 ± 17.59—
Global Health Status C26D16.41 ± 23.11—
Global Health Status C27D12.27 ± 22.39—
Global Health Status C28D10.69 ± 26.93—
Global Health Status 30 Day follow up-4.98 ± 21.20-4.03 ± 20.99
Global Health Status 90 Day follow up-5.72 ± 21.55-4.62 ± 22.32
Physical Functioning Baseline79.71 ± 20.3778.79 ± 21.13
Physical Functioning C1D22-4.22 ± 17.23-1.49 ± 15.70
Physical Functioning C2D1-1.90 ± 18.801.69 ± 17.92
Physical Functioning C2D22-0.98 ± 17.691.73 ± 18.69
Physical Functioning C3D1-0.84 ± 19.512.66 ± 18.70
Physical Functioning C3D22-1.36 ± 17.261.52 ± 15.88
Physical Functioning C4D10.12 ± 19.691.47 ± 19.25
Physical Functioning C4D22-2.60 ± 19.87-1.51 ± 19.61
Physical Functioning C5D1-3.00 ± 22.550.55 ± 18.86
Physical Functioning C5D22-2.52 ± 22.470.11 ± 19.72
Physical Functioning C6D1-1.08 ± 20.91-1.26 ± 18.92
Physical Functioning C6D22-2.01 ± 22.59-0.92 ± 15.96
Physical Functioning C7D1-1.35 ± 21.67-0.95 ± 15.58
Physical Functioning C7D22-2.14 ± 18.671.89 ± 19.03
Physical Functioning C8D10.33 ± 21.870.88 ± 15.85
Physical Functioning C8D221.02 ± 18.84-0.31 ± 17.66
Physical Functioning C9D12.13 ± 20.330.43 ± 17.24
Physical Functioning C9D222.78 ± 23.461.94 ± 16.61
Physical Functioning C10D12.53 ± 21.650.71 ± 16.26
Physical Functioning C10D223.27 ± 18.61-2.48 ± 19.36
Physical Functioning C11D13.60 ± 20.17-3.33 ± 16.91
Physical Functioning C11D223.33 ± 18.72-6.02 ± 16.18
Physical Functioning C12D12.26 ± 20.08-3.58 ± 14.61
Physical Functioning C12D222.63 ± 20.65-5.60 ± 14.74
Physical Functioning C13D13.06 ± 20.35-6.67 ± 17.26
Physical Functioning C13D221.46 ± 21.63-6.98 ± 19.60
Physical Functioning C14D14.27 ± 17.27-3.56 ± 13.30
Physical Functioning C14D220.42 ± 19.67-1.75 ± 13.49
Physical Functioning C15D13.24 ± 18.39-6.42 ± 18.35
Physical Functioning C15D223.56 ± 18.260.39 ± 14.43
Physical Functioning C16D13.43 ± 20.98-4.55 ± 18.79
Physical Functioning C16D225.29 ± 19.39-7.14 ± 14.67
Physical Functioning C17D13.78 ± 25.05-3.70 ± 11.93
Physical Functioning C17D22-3.19 ± 26.20—
Physical Functioning C18D13.46 ± 21.03-2.92 ± 6.87
Physical Functioning C18D223.17 ± 20.830.00 ± 7.03
Physical Functioning C19D13.48 ± 17.39-1.33 ± 8.05
Physical Functioning C19D22-1.00 ± 18.39-4.24 ± 8.58
Physical Functioning C20D10.29 ± 22.43-1.78 ± 8.90
Physical Functioning C20D22-1.48 ± 24.37-4.67 ± 7.73
Physical Functioning C21D12.33 ± 15.18-1.43 ± 9.13
Physical Functioning C21D22-3.33 ± 18.07—
Physical Functioning C22D13.11 ± 18.83-2.22 ± 6.56
Physical Functioning C22D22-5.45 ± 24.00—
Physical Functioning C23D1-3.33 ± 19.781.54 ± 9.49
Physical Functioning C23D221.82 ± 15.23—
Physical Functioning C24D1-3.81 ± 21.36—
Physical Functioning C25D15.00 ± 11.42—
Physical Functioning C25D222.42 ± 15.28—
Physical Functioning C26D13.08 ± 14.56—
Physical Functioning C27D13.64 ± 15.88—
Physical Functioning C28D11.67 ± 15.86—
Physical Functioning 30 Day follow up-9.26 ± 24.63-6.96 ± 21.73
Physical Functioning 90 Day follow up-13.57 ± 23.77-11.49 ± 25.95
Role Functioning Baseline74.77 ± 27.5675.52 ± 28.02
Role Functioning C1D22-6.78 ± 25.09-4.13 ± 24.10
Role Functioning C2D1-0.64 ± 26.780.30 ± 25.92
Role Functioning C2D22-1.67 ± 25.82-1.20 ± 28.44
Role Functioning C3D10.96 ± 28.022.19 ± 26.57
Role Functioning C3D22-3.73 ± 25.96-0.89 ± 25.98
Role Functioning C4D1-1.18 ± 28.411.94 ± 26.92
Role Functioning C4D22-2.98 ± 28.39-2.73 ± 24.82
Role Functioning C5D1-4.25 ± 29.71-2.87 ± 27.24
Role Functioning C5D22-2.70 ± 30.03-2.73 ± 27.88
Role Functioning C6D1-1.76 ± 29.94-5.46 ± 26.19
Role Functioning C6D22-4.21 ± 29.59-2.84 ± 25.47
Role Functioning C7D1-5.56 ± 28.37-2.55 ± 22.75
Role Functioning C7D22-5.35 ± 29.68-1.58 ± 24.08
Role Functioning C8D1-2.92 ± 29.62-0.60 ± 23.20
Role Functioning C8D22-1.39 ± 28.22-1.03 ± 21.83
Role Functioning C9D14.89 ± 26.53-2.96 ± 22.49
Role Functioning C9D22-0.83 ± 30.13-0.61 ± 22.21
Role Functioning C10D10.00 ± 29.38-3.27 ± 26.1
Role Functioning C10D22-0.58 ± 30.37-2.71 ± 26.96
Role Functioning C11D11.32 ± 32.56-0.36 ± 21.28
Role Functioning C11D22-3.79 ± 28.27-9.14 ± 20.11
Role Functioning C12D1-0.63 ± 26.55-2.85 ± 21.38
Role Functioning C12D22-5.26 ± 28.24-4.0 ± 24.19
Role Functioning C13D1-1.04 ± 29.86-2.38 ± 24.30
Role Functioning C13D22-4.88 ± 29.400.00 ± 19.0
Role Functioning C14D1-2.99 ± 26.18-5.56 ± 20.22
Role Functioning C14D22-3.65 ± 27.67-2.63 ± 20.23
Role Functioning C15D1-1.90 ± 27.94-5.56 ± 24.46
Role Functioning C15D22-5.00 ± 31.005.88 ± 22.00
Role Functioning C16D10.48 ± 30.380.00 ± 23.00
Role Functioning C16D22-6.32 ± 31.94-1.19 ± 20.11
Role Functioning C17D1-0.56 ± 33.760.00 ± 16.17
Role Functioning C17D22-11.59 ± 36.73—
Role Functioning C18D1-4.32 ± 28.72-1.04 ± 14.23
Role Functioning C18D22-3.17 ± 24.51-1.67 ± 14.59
Role Functioning C19D1-3.62 ± 24.60-5.56 ± 19.59
Role Functioning C19D22-8.33 ± 18.34-3.03 ± 19.46
Role Functioning C20D1-5.80 ± 23.36-4.44 ± 20.38
Role Functioning C20D22-6.48 ± 33.40-6.67 ± 11.65
Role Functioning C21D12.50 ± 21.81-1.19 ± 17.86
Role Functioning C21D22-5.95 ± 21.29—
Role Functioning C22D1-2.22 ± 15.26-2.78 ± 18.58
Role Functioning C22D22-13.64 ± 36.38—
Role Functioning C23D1-6.25 ± 28.461.28 ± 12.66
Role Functioning C23D22-4.55 ± 22.47—
Role Functioning C24D1-7.14 ± 26.73—
Role Functioning C25D1-4.17 ± 20.26—
Role Functioning C25D22-12.12 ± 18.40—
Role Functioning C26D1-11.54 ± 19.70—
Role Functioning C27D1-6.06 ± 22.70—
Role Functioning C28D1-6.94 ± 24.06—
Role Functioning 30 Day follow up-13.19 ± 29.46-10.99 ± 30.65
Role Functioning 90 Day follow up-14.53 ± 33.90-14.26 ± 29.58
Emotional Functioning Baseline74.64 ± 20.7173.45 ± 21.16
Emotional Functioning C1D220.85 ± 19.083.33 ± 15.96
Emotional Functioning C2D14.55 ± 20.496.15 ± 17.93
Emotional Functioning C2D225.78 ± 19.365.85 ± 18.69
Emotional Functioning C3D16.27 ± 20.289.43 ± 18.44
Emotional Functioning C3D223.62 ± 21.149.06 ± 19.35
Emotional Functioning C4D17.40 ± 20.208.13 ± 18.86
Emotional Functioning C4D222.71 ± 19.466.84 ± 20.98
Emotional Functioning C5D14.19 ± 24.215.80 ± 20.23
Emotional Functioning C5D224.35 ± 24.042.95 ± 18.17
Emotional Functioning C6D16.44 ± 24.564.92 ± 17.86
Emotional Functioning C6D225.50 ± 21.447.54 ± 17.96
Emotional Functioning C7D15.70 ± 22.247.99 ± 19.59
Emotional Functioning C7D223.70 ± 20.207.66 ± 18.90
Emotional Functioning C8D15.21 ± 19.649.14 ± 19.42
Emotional Functioning C8D227.29 ± 24.586.41 ± 20.35
Emotional Functioning C9D18.67 ± 23.866.99 ± 16.05
Emotional Functioning C9D226.11 ± 25.255.76 ± 18.69
Emotional Functioning C10D17.20 ± 23.976.85 ± 18.26
Emotional Functioning C10D228.04 ± 22.276.20 ± 20.50
Emotional Functioning C11D19.13 ± 20.833.99 ± 21.14
Emotional Functioning C11D228.33 ± 17.881.88 ± 22.64
Emotional Functioning C12D19.59 ± 19.572.44 ± 18.66
Emotional Functioning C12D223.95 ± 19.254.33 ± 18.65
Emotional Functioning C13D17.99 ± 23.441.43 ± 24.38
Emotional Functioning C13D223.86 ± 20.34-3.17 ± 19.63
Emotional Functioning C14D16.20 ± 21.612.22 ± 18.94
Emotional Functioning C14D223.65 ± 21.27-1.75 ± 18.96
Emotional Functioning C15D16.43 ± 21.492.47 ± 18.46
Emotional Functioning C15D224.17 ± 16.63-2.45 ± 20.99
Emotional Functioning C16D19.76 ± 21.81-3.41 ± 21.62
Emotional Functioning C16D226.03 ± 19.02-4.76 ± 20.60
Emotional Functioning C17D17.50 ± 28.903.70 ± 19.43
Emotional Functioning C17D227.25 ± 23.21—
Emotional Functioning C18D18.33 ± 20.282.60 ± 20.12
Emotional Functioning C18D225.95 ± 18.47-5.00 ± 21.59
Emotional Functioning C19D18.70 ± 23.09-2.22 ± 19.02
Emotional Functioning C19D224.17 ± 24.26-3.79 ± 20.87
Emotional Functioning C20D110.51 ± 17.272.78 ± 20.33
Emotional Functioning C20D228.80 ± 17.26-6.67 ± 19.95
Emotional Functioning C21D111.25 ± 18.39-2.98 ± 24.59
Emotional Functioning C21D226.55 ± 16.40—
Emotional Functioning C22D111.67 ± 16.612.78 ± 21.42
Emotional Functioning C22D22-2.27 ± 27.41—
Emotional Functioning C23D17.81 ± 19.365.13 ± 21.93
Emotional Functioning C23D224.55 ± 17.62—
Emotional Functioning C24D114.88 ± 20.72—
Emotional Functioning C25D19.03 ± 21.75—
Emotional Functioning C25D221.52 ± 22.92—
Emotional Functioning C26D110.90 ± 24.86—
Emotional Functioning C27D113.64 ± 18.36—
Emotional Functioning C28D114.58 ± 21.36—
Emotional Functioning 30 Day follow up-2.55 ± 22.19-2.47 ± 19.90
Emotional Functioning 90 Day follow up-1.74 ± 22.69-4.02 ± 23.65
Cognitive Functioning Baseline87.48 ± 17.6286.69 ± 18.35
Cognitive Functioning C1D22-3.01 ± 18.04-0.32 ± 14.49
Cognitive Functioning C2D1-0.16 ± 19.570.30 ± 15.98
Cognitive Functioning C2D22-1.00 ± 16.75-1.10 ± 15.38
Cognitive Functioning C3D1-0.61 ± 20.67-0.17 ± 16.19
Cognitive Functioning C3D22-3.07 ± 18.83-0.11 ± 13.49
Cognitive Functioning C4D10.10 ± 19.82-1.64 ± 15.85
Cognitive Functioning C4D22-5.28 ± 21.59-1.82 ± 16.10
Cognitive Functioning C5D1-4.03 ± 21.19-3.56 ± 17.26
Cognitive Functioning C5D22-4.35 ± 23.54-3.16 ± 16.14
Cognitive Functioning C6D1-5.42 ± 24.00-3.13 ± 17.22
Cognitive Functioning C6D22-2.27 ± 23.46-0.71 ± 14.85
Cognitive Functioning C7D1-2.49 ± 19.36-3.57 ± 17.46
Cognitive Functioning C7D22-2.06 ± 18.33-0.45 ± 16.08
Cognitive Functioning C8D1-3.75 ± 21.38-2.61 ± 16.97
Cognitive Functioning C8D221.16 ± 22.08-5.90 ± 20.92
Cognitive Functioning C9D1-0.67 ± 22.67-2.15 ± 17.72
Cognitive Functioning C9D22-1.67 ± 24.100.91 ± 18.26
Cognitive Functioning C10D1-0.25 ± 23.11-2.68 ± 17.05
Cognitive Functioning C10D22-1.17 ± 19.63-3.10 ± 21.60
Cognitive Functioning C11D12.12 ± 19.74-2.90 ± 20.28
Cognitive Functioning C11D22-2.27 ± 15.91-4.30 ± 19.71
Cognitive Functioning C12D10.00 ± 18.20-1.63 ± 18.56
Cognitive Functioning C12D22-1.75 ± 19.68-6.00 ± 15.87
Cognitive Functioning C13D11.04 ± 18.96-5.24 ± 28.23
Cognitive Functioning C13D22-1.22 ± 20.20-1.59 ± 25.77
Cognitive Functioning C14D10.43 ± 18.92-3.89 ± 20.85
Cognitive Functioning C14D22-4.17 ± 21.17-3.51 ± 24.58
Cognitive Functioning C15D1-1.43 ± 24.041.23 ± 15.28
Cognitive Functioning C15D22-0.56 ± 17.223.92 ± 24.67
Cognitive Functioning C16D11.43 ± 18.24-2.27 ± 26.38
Cognitive Functioning C16D22-1.15 ± 18.86-1.19 ± 17.86
Cognitive Functioning C17D1-0.56 ± 25.70-2.78 ± 16.42
Cognitive Functioning C17D22-2.17 ± 23.73—
Cognitive Functioning C18D1-0.62 ± 19.870.00 ± 10.54
Cognitive Functioning C18D220.00 ± 20.41-3.33 ± 10.54
Cognitive Functioning C19D1-1.45 ± 18.74-2.22 ± 10.67
Cognitive Functioning C19D22-5.00 ± 20.301.52 ± 11.68
Cognitive Functioning C20D1-2.90 ± 19.241.11 ± 11.73
Cognitive Functioning C20D220.93 ± 17.590.00 ± 7.86
Cognitive Functioning C21D10.00 ± 15.29-2.38 ± 12.84
Cognitive Functioning C21D22-2.38 ± 14.41—
Cognitive Functioning C22D10.00 ± 16.67-1.39 ± 13.22
Cognitive Functioning C22D224.55 ± 19.85—
Cognitive Functioning C23D1-1.04 ± 17.712.56 ± 9.25
Cognitive Functioning C23D221.52 ± 15.73—
Cognitive Functioning C24D12.38 ± 18.32—
Cognitive Functioning C25D14.17 ± 14.43—
Cognitive Functioning C25D220.00 ± 16.67—
Cognitive Functioning C26D12.56 ± 19.06—
Cognitive Functioning C27D16.06 ± 18.67—
Cognitive Functioning C28D14.17 ± 18.97—
Cognitive Functioning 30 Day follow up-8.56 ± 24.54-6.41 ± 17.70
Cognitive Functioning 90 Day follow up-11.63 ± 21.25-7.83 ± 20.22
Social Functioning Baseline75.36 ± 25.7773.26 ± 27.18
Social Functioning C1D22-3.11 ± 24.130.48 ± 23.05
Social Functioning C2D1-0.32 ± 24.243.11 ± 25.69
Social Functioning C2D22-2.44 ± 23.042.76 ± 27.47
Social Functioning C3D10.53 ± 25.312.44 ± 26.78
Social Functioning C3D22-5.70 ± 25.093.80 ± 25.86
Social Functioning C4D10.20 ± 24.865.62 ± 23.88
Social Functioning C4D22-0.95 ± 25.282.73 ± 22.21
Social Functioning C5D1-1.57 ± 29.211.38 ± 29.43
Social Functioning C5D22-0.75 ± 28.370.86 ± 27.26
Social Functioning C6D10.54 ± 24.510.27 ± 26.42
Social Functioning C6D221.29 ± 24.443.01 ± 29.33
Social Functioning C7D1-1.61 ± 24.490.00 ± 24.87
Social Functioning C7D22-1.03 ± 26.664.50 ± 26.21
Social Functioning C8D1-0.83 ± 21.533.01 ± 22.56
Social Functioning C8D221.85 ± 21.041.03 ± 24.09
Social Functioning C9D12.67 ± 21.053.23 ± 25.22
Social Functioning C9D222.78 ± 21.523.33 ± 26.91
Social Functioning C10D13.03 ± 23.19-0.60 ± 28.60
Social Functioning C10D222.34 ± 21.69-1.55 ± 30.82
Social Functioning C11D13.70 ± 21.881.81 ± 25.87
Social Functioning C11D22-0.76 ± 21.55-3.76 ± 22.65
Social Functioning C12D14.09 ± 17.870.00 ± 26.09
Social Functioning C12D22-1.32 ± 21.714.00 ± 22.71
Social Functioning C13D12.43 ± 21.191.43 ± 26.62
Social Functioning C13D221.22 ± 23.398.73 ± 22.74
Social Functioning C14D12.99 ± 22.250.56 ± 25.33
Social Functioning C14D220.52 ± 20.526.14 ± 23.71
Social Functioning C15D12.38 ± 28.34-6.17 ± 24.96
Social Functioning C15D223.89 ± 20.380.00 ± 22.05
Social Functioning C16D13.33 ± 22.433.79 ± 24.09
Social Functioning C16D221.15 ± 22.243.57 ± 26.29
Social Functioning C17D11.67 ± 26.754.63 ± 26.69
Social Functioning C17D22-3.62 ± 22.45—
Social Functioning C18D11.85 ± 21.85-1.04 ± 20.61
Social Functioning C18D222.38 ± 16.06-6.67 ± 11.65
Social Functioning C19D13.62 ± 16.63-5.56 ± 16.27
Social Functioning C19D220.83 ± 11.44-4.55 ± 16.82
Social Functioning C20D12.17 ± 19.66-3.33 ± 19.11
Social Functioning C20D221.85 ± 15.005.00 ± 13.72
Social Functioning C21D16.67 ± 16.58-11.90 ± 15.23
Social Functioning C21D227.14 ± 15.63—
Social Functioning C22D11.11 ± 20.38-4.17 ± 16.09
Social Functioning C22D22-4.55 ± 21.20—
Social Functioning C23D11.04 ± 17.71-2.56 ± 16.45
Social Functioning C23D224.55 ± 19.85—
Social Functioning C24D12.38 ± 23.44—
Social Functioning C25D12.78 ± 29.16—
Social Functioning C25D223.03 ± 19.46—
Social Functioning C26D12.56 ± 21.35—
Social Functioning C27D16.06 ± 23.89—
Social Functioning C28D15.56 ± 20.52—
Social Functioning 30 Day follow up-12.73 ± 30.45-2.56 ± 26.98
Social Functioning 90 Day follow up-9.88 ± 29.64-6.02 ± 27.74
Fatigue Baseline31.13 ± 23.9432.69 ± 23.71
Fatigue C1D228.47 ± 23.124.50 ± 20.34
Fatigue C2D13.81 ± 22.20-1.48 ± 22.30
Fatigue C2D224.00 ± 22.75-0.06 ± 21.90
Fatigue C3D12.11 ± 23.61-2.13 ± 21.92
Fatigue C3D228.48 ± 23.15-0.37 ± 21.47
Fatigue C4D11.70 ± 25.04-1.30 ± 23.34
Fatigue C4D225.96 ± 24.03-1.48 ± 22.80
Fatigue C5D14.85 ± 26.790.38 ± 24.82
Fatigue C5D225.61 ± 27.941.82 ± 25.12
Fatigue C6D11.08 ± 25.662.00 ± 22.86
Fatigue C6D222.05 ± 24.74-0.35 ± 21.83
Fatigue C7D10.78 ± 22.74-1.81 ± 21.15
Fatigue C7D224.53 ± 22.21-1.35 ± 21.21
Fatigue C8D1-0.14 ± 23.95-1.34 ± 23.11
Fatigue C8D22-0.77 ± 22.71-1.03 ± 23.38
Fatigue C9D1-4.30 ± 22.81-3.58 ± 21.55
Fatigue C9D22-0.74 ± 24.28-3.23 ± 23.00
Fatigue C10D1-1.18 ± 23.88-3.97 ± 23.82
Fatigue C10D22-0.39 ± 21.920.26 ± 22.55
Fatigue C11D1-4.23 ± 20.30-1.21 ± 20.45
Fatigue C11D22-3.79 ± 19.31-0.36 ± 21.94
Fatigue C12D1-3.98 ± 19.130.54 ± 20.63
Fatigue C12D221.17 ± 18.042.67 ± 22.52
Fatigue C13D1-1.16 ± 21.773.17 ± 23.43
Fatigue C13D221.36 ± 23.072.65 ± 16.06
Fatigue C14D10.00 ± 20.711.48 ± 20.37
Fatigue C14D220.00 ± 21.49-0.58 ± 20.11
Fatigue C15D13.49 ± 25.254.94 ± 23.54
Fatigue C15D222.96 ± 9.12-7.19 ± 21.50
Fatigue C16D1-2.22 ± 22.510.51 ± 21.54
Fatigue C16D221.53 ± 27.332.38 ± 23.13
Fatigue C17D11.85 ± 22.24-0.62 ± 23.33
Fatigue C17D228.70 ± 26.58—
Fatigue C18D1-2.88 ± 18.64-2.78 ± 21.66
Fatigue C18D22-4.23 ± 17.731.11 ± 20.59
Fatigue C19D1-0.48 ± 23.082.96 ± 25.36
Fatigue C19D22-1.11 ± 19.713.03 ± 26.80
Fatigue C20D11.45 ± 26.65-1.48 ± 15.64
Fatigue C20D224.32 ± 29.802.22 ± 18.74
Fatigue C21D1-4.44 ± 15.88-0.79 ± 19.72
Fatigue C21D228.73 ± 21.43—
Fatigue C22D15.19 ± 20.522.78 ± 17.81
Fatigue C22D229.09 ± 29.32—
Fatigue C23D111.11 ± 22.22-1.71 ± 19.16
Fatigue C23D227.07 ± 18.10—
Fatigue C24D16.35 ± 22.10—
Fatigue C25D16.48 ± 15.32—
Fatigue C25D228.08 ± 20.54—
Fatigue C26D13.42 ± 17.79—
Fatigue C27D11.01 ± 14.45—
Fatigue C28D13.70 ± 15.95—
Fatigue 30 Day follow up8.02 ± 26.326.96 ± 25.80
Fatigue 90 Day follow up11.63 ± 29.1213.25 ± 25.35
Nausea and Vomiting Baseline15.37 ± 23.9017.18 ± 24.33
Nausea and Vomiting C1D229.13 ± 23.772.70 ± 23.19
Nausea and Vomiting C2D13.38 ± 25.90-3.70 ± 23.85
Nausea and Vomiting C2D224.33 ± 23.760.83 ± 26.25
Nausea and Vomiting C3D10.53 ± 27.43-5.13 ± 23.70
Nausea and Vomiting C3D224.61 ± 24.28-1.68 ± 28.19
Nausea and Vomiting C4D10.00 ± 26.46-4.19 ± 23.74
Nausea and Vomiting C4D222.30 ± 25.46-3.39 ± 25.48
Nausea and Vomiting C5D1-0.22 ± 23.00-6.78 ± 23.69
Nausea and Vomiting C5D222.40 ± 21.65-5.60 ± 22.08
Nausea and Vomiting C6D1-2.98 ± 19.33-3.42 ± 24.24
Nausea and Vomiting C6D22-1.13 ± 22.54-5.14 ± 24.32
Nausea and Vomiting C7D1-2.63 ± 19.40-4.25 ± 21.31
Nausea and Vomiting C7D222.06 ± 21.31-6.53 ± 22.21
Nausea and Vomiting C8D1-1.46 ± 18.41-3.61 ± 16.68
Nausea and Vomiting C8D22-1.85 ± 22.12-4.10 ± 21.86
Nausea and Vomiting C9D1-6.22 ± 20.46-4.57 ± 23.80
Nausea and Vomiting C9D22-0.56 ± 20.11-3.94 ± 21.98
Nausea and Vomiting C10D1-2.27 ± 21.26-3.87 ± 19.59
Nausea and Vomiting C10D22-1.17 ± 21.33-2.71 ± 25.18
Nausea and Vomiting C11D1-4.23 ± 20.95-1.81 ± 22.56
Nausea and Vomiting C11D220.38 ± 17.79-3.76 ± 24.23
Nausea and Vomiting C12D1-3.77 ± 19.51-1.63 ± 25.22
Nausea and Vomiting C12D22-1.75 ± 19.68-3.33 ± 24.06
Nausea and Vomiting C13D1-3.12 ± 19.34-3.33 ± 23.50
Nausea and Vomiting C13D22-1.63 ± 23.22-7.14 ± 24.48
Nausea and Vomiting C14D1-5.13 ± 22.99-2.78 ± 22.35
Nausea and Vomiting C14D22-2.08 ± 24.59-7.02 ± 24.42
Nausea and Vomiting C15D1-3.33 ± 23.50-3.09 ± 25.75
Nausea and Vomiting C15D22-3.89 ± 22.18-2.94 ± 31.31
Nausea and Vomiting C16D1-7.62 ± 22.631.52 ± 33.69
Nausea and Vomiting C16D22-1.72 ± 29.33-7.14 ± 30.46
Nausea and Vomiting C17D1-10.00 ± 21.71-4.63 ± 27.30
Nausea and Vomiting C17D22-1.45 ± 21.85—
Nausea and Vomiting C18D1-7.41 ± 20.84-4.17 ± 26.87
Nausea and Vomiting C18D22-3.17 ± 22.12-8.33 ± 29.66
Nausea and Vomiting C19D1-5.07 ± 21.58-1.11 ± 29.19
Nausea and Vomiting C19D22-5.00 ± 22.36-7.58 ± 31.94
Nausea and Vomiting C20D1-4.35 ± 22.60-3.33 ± 26.87
Nausea and Vomiting C20D22-4.63 ± 25.44-8.33 ± 32.63
Nausea and Vomiting C21D1-1.67 ± 16.13-3.57 ± 30.08
Nausea and Vomiting C21D22-4.76 ± 18.98—
Nausea and Vomiting C22D1-2.22 ± 20.77-9.72 ± 27.94
Nausea and Vomiting C22D22-6.06 ± 25.03—
Nausea and Vomiting C23D1-5.21 ± 19.92-3.85 ± 30.55
Nausea and Vomiting C23D22-6.06 ± 23.89—
Nausea and Vomiting C24D1-8.33 ± 21.43—
Nausea and Vomiting C25D1-8.33 ± 21.90—
Nausea and Vomiting C25D22-6.06 ± 25.03—
Nausea and Vomiting C26D1-10.26 ± 21.01—
Nausea and Vomiting C27D1-1.52 ± 8.99—
Nausea and Vomiting C28D1-4.17 ± 14.43—
Nausea and Vomiting 30 Day Follow up3.24 ± 25.12-1.10 ± 27.19
Nausea and Vomiting 90 Day Follow up0.39 ± 22.28-4.42 ± 29.34
Pain Baseline25.68 ± 25.5126.61 ± 25.13
Pain C1D22-2.54 ± 23.40-5.48 ± 19.23
Pain C2D1-6.36 ± 24.77-9.19 ± 21.93
Pain C2D22-7.67 ± 24.47-9.21 ± 23.27
Pain C3D1-9.12 ± 25.92-9.18 ± 22.56
Pain C3D22-8.44 ± 24.71-7.61 ± 22.13
Pain C4D1-9.31 ± 24.46-9.41 ± 21.68
Pain C4D22-5.69 ± 23.94-7.94 ± 22.91
Pain C5D1-5.82 ± 26.91-6.55 ± 23.27
Pain C5D22-5.41 ± 26.32-5.60 ± 24.27
Pain C6D1-7.18 ± 27.25-4.64 ± 24.17
Pain C6D22-5.34 ± 23.36-8.16 ± 18.89
Pain C7D1-5.56 ± 24.15-6.80 ± 20.56
Pain C7D22-1.65 ± 25.22-6.98 ± 20.65
Pain C8D1-2.92 ± 25.13-7.83 ± 18.28
Pain C8D22-8.10 ± 23.40-5.90 ± 17.04
Pain C9D1-8.89 ± 22.48-6.99 ± 18.74
Pain C9D22-6.11 ± 23.96-3.94 ± 21.75
Pain C10D1-6.57 ± 24.09-2.38 ± 25.71
Pain C10D22-2.92 ± 24.42-2.71 ± 24.65
Pain C11D1-9.26 ± 23.91-3.62 ± 18.56
Pain C11D22-7.20 ± 22.85-3.23 ± 15.17
Pain C12D1-7.55 ± 22.54-1.22 ± 19.50
Pain C12D22-0.88 ± 27.11-5.33 ± 20.25
Pain C13D1-5.21 ± 25.76-2.86 ± 20.41
Pain C13D22-2.03 ± 25.87-7.14 ± 21.46
Pain C14D1-4.27 ± 24.10-1.11 ± 19.54
Pain C14D22-5.73 ± 18.26-10.53 ± 26.18
Pain C15D1-4.76 ± 23.071.85 ± 25.46
Pain C15D22-5.00 ± 18.65-4.90 ± 28.73
Pain C16D1-3.81 ± 24.95-4.55 ± 22.53
Pain C16D22-6.32 ± 19.11-3.57 ± 11.65
Pain C17D10.56 ± 29.84-4.63 ± 15.97
Pain C17D222.17 ± 31.90—
Pain C18D1-3.09 ± 28.13-6.25 ± 10.32
Pain C18D22-1.59 ± 17.40-5.00 ± 15.81
Pain C19D10.00 ± 20.72-1.11 ± 13.31
Pain C19D220.00 ± 16.22-4.55 ± 10.78
Pain C20D1-2.17 ± 26.26-3.33 ± 15.69
Pain C20D22-3.70 ± 21.811.67 ± 16.57
Pain C21D1-5.83 ± 18.95-4.76 ± 15.23
Pain C21D22-2.38 ± 17.12—
Pain C22D1-1.11 ± 14.73-4.17 ± 12.56
Pain C22D220.00 ± 14.91—
Pain C23D11.04 ± 21.49-6.41 ± 14.50
Pain C23D22-1.52 ± 17.41—
Pain C24D13.57 ± 26.29—
Pain C25D15.56 ± 14.79—
Pain C25D226.06 ± 23.89—
Pain C26D11.28 ± 14.37—
Pain C27D10.00 ± 18.26—
Pain C28D11.39 ± 19.41—
Pain 30 Follow up0.46 ± 29.337.33 ± 27.24
Pain 90 Day Follow up3.49 ± 28.376.02 ± 29.51
Dyspnoea Baseline13.23 ± 22.9713.70 ± 23.20
Dyspnoea C1D221.88 ± 22.671.43 ± 22.19
Dyspnoea C2D10.48 ± 20.900.59 ± 20.88
Dyspnoea C2D22-0.67 ± 20.960.18 ± 21.52
Dyspnoea C3D10.35 ± 24.241.01 ± 20.13
Dyspnoea C3D221.32 ± 21.322.24 ± 21.10
Dyspnoea C4D1-0.20 ± 23.361.43 ± 21.07
Dyspnoea C4D222.71 ± 20.290.26 ± 20.28
Dyspnoea C5D12.24 ± 20.75-0.46 ± 24.21
Dyspnoea C5D222.10 ± 22.151.44 ± 22.15
Dyspnoea C6D10.81 ± 22.773.28 ± 22.02
Dyspnoea C6D220.65 ± 20.861.42 ± 20.69
Dyspnoea C7D14.09 ± 21.33-1.02 ± 19.42
Dyspnoea C7D224.94 ± 19.80-2.25 ± 21.60
Dyspnoea C8D13.75 ± 20.54-0.40 ± 21.77
Dyspnoea C8D221.85 ± 18.46-3.59 ± 18.75
Dyspnoea C9D11.78 ± 18.90-3.23 ± 19.75
Dyspnoea C9D223.33 ± 27.92-3.64 ± 21.92
Dyspnoea C10D11.52 ± 25.100.00 ± 22.92
Dyspnoea C10D222.34 ± 18.751.55 ± 24.07
Dyspnoea C11D1-0.53 ± 17.450.00 ± 17.21
Dyspnoea C11D222.27 ± 18.182.15 ± 28.46
Dyspnoea C12D14.40 ± 16.060.00 ± 21.08
Dyspnoea C12D222.63 ± 16.225.33 ± 15.75
Dyspnoea C13D12.78 ± 15.120.95 ± 22.12
Dyspnoea C13D223.25 ± 16.34-1.59 ± 26.82
Dyspnoea C14D10.85 ± 16.200.00 ± 24.76
Dyspnoea C14D220.00 ± 16.93-3.51 ± 26.98
Dyspnoea C15D1-0.95 ± 20.59-1.23 ± 26.92
Dyspnoea C15D22-2.22 ± 14.99-3.92 ± 28.58
Dyspnoea C16D11.90 ± 13.87-1.52 ± 26.18
Dyspnoea C16D224.60 ± 19.364.76 ± 17.82
Dyspnoea C17D12.22 ± 17.360.00 ± 16.17
Dyspnoea C17D222.90 ± 19.88—
Dyspnoea C18D10.00 ± 13.072.08 ± 19.12
Dyspnoea C18D224.76 ± 19.11-3.33 ± 18.92
Dyspnoea C19D12.90 ± 13.90-2.22 ± 15.26
Dyspnoea C19D223.33 ± 14.910.00 ± 25.82
Dyspnoea C20D11.45 ± 12.222.22 ± 23.46
Dyspnoea C20D221.85 ± 7.86-6.67 ± 14.05
Dyspnoea C21D10.00 ± 0.004.76 ± 25.68
Dyspnoea C21D222.38 ± 8.91—
Dyspnoea C22D1-2.22 ± 8.610.00 ± 20.10
Dyspnoea C22D220.00 ± 14.91—
Dyspnoea C23D16.25 ± 21.840.00 ± 19.25
Dyspnoea C23D220.00 ± 14.91—
Dyspnoea C24D10.00 ± 13.07—
Dyspnoea C25D1-5.56 ± 12.97—
Dyspnoea C25D22-3.03 ± 10.05—
Dyspnoea C26D1-2.56 ± 9.25—
Dyspnoea C27D10.00 ± 14.91—
Dyspnoea C28D1-2.78 ± 9.62—
Dyspnoea 30 Day Follow up4.63 ± 23.945.49 ± 21.81
Dyspnoea 90 Day Follow up13.57 ± 29.9812.05 ± 27.83
Insomnia Baseline27.50 ± 28.5029.59 ± 28.64
Insomnia C1D220.00 ± 27.52-3.81 ± 29.28
Insomnia C2D1-4.03 ± 29.92-6.22 ± 29.73
Insomnia C2D22-5.33 ± 29.18-8.84 ± 28.68
Insomnia C3D1-8.42 ± 30.85-10.27 ± 30.98
Insomnia C3D22-5.26 ± 27.69-10.07 ± 31.17
Insomnia C4D1-10.59 ± 29.55-11.86 ± 30.47
Insomnia C4D22-5.42 ± 31.47-11.46 ± 29.11
Insomnia C5D1-5.59 ± 32.28-8.97 ± 34.30
Insomnia C5D22-6.01 ± 32.47-7.47 ± 30.16
Insomnia C6D1-6.50 ± 32.13-8.47 ± 31.36
Insomnia C6D22-4.21 ± 29.03-12.77 ± 30.57
Insomnia C7D1-7.02 ± 27.86-11.90 ± 28.82
Insomnia C7D22-4.94 ± 23.64-13.96 ± 25.29
Insomnia C8D1-6.67 ± 26.73-8.84 ± 29.49
Insomnia C8D22-6.94 ± 27.37-14.36 ± 24.98
Insomnia C9D1-8.44 ± 29.05-13.98 ± 25.99
Insomnia C9D22-8.89 ± 32.97-11.52 ± 30.24
Insomnia C10D1-8.59 ± 27.62-8.33 ± 33.78
Insomnia C10D22-9.94 ± 26.70-10.85 ± 29.74
Insomnia C11D1-8.99 ± 27.57-10.14 ± 26.17
Insomnia C11D22-11.36 ± 26.84-10.75 ± 29.04
Insomnia C12D1-8.18 ± 29.17-12.20 ± 30.51
Insomnia C12D22-3.51 ± 26.61-8.00 ± 25.96
Insomnia C13D1-6.25 ± 32.73-10.48 ± 22.54
Insomnia C13D22-9.76 ± 28.13-11.11 ± 19.25
Insomnia C14D1-9.40 ± 25.30-5.56 ± 27.80
Insomnia C14D22-7.29 ± 29.00-8.77 ± 26.86
Insomnia C15D1-7.62 ± 30.34-6.17 ± 24.52
Insomnia C15D22-8.89 ± 26.16-3.92 ± 26.04
Insomnia C16D1-9.52 ± 28.66-1.52 ± 24.07
Insomnia C16D22-9.20 ± 23.40-7.14 ± 29.75
Insomnia C17D1-4.44 ± 33.60-7.41 ± 29.27
Insomnia C17D22-4.35 ± 30.66—
Insomnia C18D1-9.88 ± 28.960.00 ± 21.08
Insomnia C18D22-1.59 ± 28.826.67 ± 21.08
Insomnia C19D1-8.70 ± 28.81-2.22 ± 29.46
Insomnia C19D22-8.33 ± 28.3612.12 ± 22.47
Insomnia C20D1-10.14 ± 29.19-4.44 ± 21.33
Insomnia C20D22-9.26 ± 31.9410.00 ± 27.44
Insomnia C21D1-6.67 ± 25.592.38 ± 27.62
Insomnia C21D22-9.52 ± 24.21—
Insomnia C22D1-6.67 ± 25.822.78 ± 22.29
Insomnia C22D22-3.03 ± 27.71—
Insomnia C23D1-2.08 ± 28.46-2.56 ± 25.32
Insomnia C23D22-6.06 ± 29.13—
Insomnia C24D1-7.14 ± 26.73—
Insomnia C25D10.00 ± 24.62—
Insomnia C25D22-3.03 ± 31.46—
Insomnia C26D1-7.69 ± 27.74—
Insomnia C27D1-9.09 ± 30.15—
Insomnia C28D1-5.56 ± 27.83—
Insomnia 30 Day Follow up-2.31 ± 28.71-2.93 ± 33.94
Insomnia 90 Day Follow up1.94 ± 29.53-3.21 ± 39.51
Appetite Loss Baseline32.81 ± 32.1432.17 ± 31.44
Appetite Loss C1D229.04 ± 33.054.13 ± 33.00
Appetite Loss C2D1-4.99 ± 36.01-8.00 ± 31.74
Appetite Loss C2D22-1.33 ± 34.080.18 ± 35.57
Appetite Loss C3D1-8.07 ± 34.53-8.75 ± 31.18
Appetite Loss C3D222.19 ± 35.71-2.68 ± 30.39
Appetite Loss C4D1-6.08 ± 38.49-7.36 ± 34.35
Appetite Loss C4D221.90 ± 38.01-4.95 ± 31.05
Appetite Loss C5D1-4.03 ± 35.92-8.28 ± 30.31
Appetite Loss C5D22-0.30 ± 37.20-6.03 ± 30.33
Appetite Loss C6D1-6.50 ± 37.37-5.19 ± 31.50
Appetite Loss C6D22-6.15 ± 39.81-8.51 ± 30.50
Appetite Loss C7D1-9.65 ± 36.76-10.20 ± 28.48
Appetite Loss C7D22-4.94 ± 39.48-11.26 ± 31.35
Appetite Loss C8D1-8.75 ± 35.48-8.43 ± 28.91
Appetite Loss C8D22-8.80 ± 38.76-4.10 ± 28.57
Appetite Loss C9D1-15.56 ± 34.37-5.91 ± 32.24
Appetite Loss C9D22-13.33 ± 41.26-1.82 ± 27.53
Appetite Loss C10D1-10.10 ± 38.33-5.36 ± 27.54
Appetite Loss C10D22-5.85 ± 37.860.78 ± 33.72
Appetite Loss C11D1-15.34 ± 36.82-2.17 ± 28.46
Appetite Loss C11D22-12.12 ± 33.79-6.45 ± 31.53
Appetite Loss C12D1-10.69 ± 33.83-5.69 ± 28.77
Appetite Loss C12D221.75 ± 31.90-5.33 ± 28.35
Appetite Loss C13D1-9.72 ± 33.66-4.76 ± 30.40
Appetite Loss C13D22-5.69 ± 39.377.94 ± 29.64
Appetite Loss C14D1-10.26 ± 35.170.00 ± 27.68
Appetite Loss C14D22-6.25 ± 39.20-7.02 ± 21.02
Appetite Loss C15D1-6.67 ± 39.44-6.17 ± 27.79
Appetite Loss C15D22-5.56 ± 42.96-7.84 ± 25.08
Appetite Loss C16D1-14.29 ± 27.16-7.58 ± 22.84
Appetite Loss C16D22-6.90 ± 39.22-7.14 ± 23.31
Appetite Loss C17D1-12.22 ± 33.31-5.56 ± 23.57
Appetite Loss C17D22-4.35 ± 32.26—
Appetite Loss C18D1-14.81 ± 31.12-4.17 ± 29.50
Appetite Loss C18D22-7.94 ± 27.70-10.00 ± 27.44
Appetite Loss C19D1-11.59 ± 23.80-2.22 ± 29.46
Appetite Loss C19D22-8.33 ± 23.88-6.06 ± 25.03
Appetite Loss C20D1-10.14 ± 27.40-8.89 ± 23.46
Appetite Loss C20D221.85 ± 33.28-10.00 ± 27.44
Appetite Loss C21D1-6.67 ± 23.20-7.14 ± 19.30
Appetite Loss C21D22-7.14 ± 23.31—
Appetite Loss C22D1-13.33 ± 21.08-11.11 ± 25.95
Appetite Loss C22D22-6.06 ± 32.72—
Appetite Loss C23D1-6.25 ± 25.00-7.69 ± 27.74
Appetite Loss C2322-9.09 ± 26.21—
Appetite Loss C24D1-11.90 ± 24.83—
Appetite Loss C25D1-2.78 ± 33.21—
Appetite Loss C25D22-3.03 ± 27.71—
Appetite Loss C26D1-10.26 ± 28.50—
Appetite Loss C27D1-3.03 ± 17.98—
Appetite Loss C28D10.00 ± 28.43—
Appetite Loss 30 Day Follow up2.31 ± 31.813.30 ± 32.60
Appetite Loss 90 Day Follow up-5.04 ± 35.627.63 ± 39.07
Constipation Baseline19.33 ± 28.1519.64 ± 28.39
Constipation C1D228.66 ± 32.964.44 ± 29.91
Constipation C2D1-0.48 ± 33.25-2.37 ± 32.80
Constipation C2D22-2.89 ± 31.120.37 ± 31.23
Constipation C3D1-5.09 ± 31.29-2.53 ± 30.40
Constipation C3D22-2.85 ± 28.18-0.89 ± 31.70
Constipation C4D1-2.75 ± 32.11-1.02 ± 28.79
Constipation C4D221.08 ± 31.922.08 ± 28.91
Constipation C5D1-2.24 ± 31.16-1.15 ± 30.79
Constipation C5D222.70 ± 31.83-1.44 ± 26.88
Constipation C6D1-2.44 ± 28.040.55 ± 28.42
Constipation C6D22-3.24 ± 27.82-1.77 ± 30.67
Constipation C7D1-2.63 ± 29.80-1.36 ± 29.08
Constipation C7D22-2.47 ± 25.70-4.05 ± 32.62
Constipation C8D1-4.17 ± 27.75-0.40 ± 29.67
Constipation C8D22-6.94 ± 29.04-2.56 ± 25.21
Constipation C9D1-8.44 ± 26.900.00 ± 28.95
Constipation C9D22-3.33 ± 32.882.42 ± 33.24
Constipation C10D1-2.02 ± 29.744.17 ± 30.53
Constipation C10D22-1.17 ± 22.687.75 ± 31.57
Constipation C11D1-4.23 ± 24.317.25 ± 31.36
Constipation C11D22-4.55 ± 26.506.45 ± 24.97
Constipation C12D1-6.29 ± 22.7010.57 ± 32.86
Constipation C12D221.75 ± 29.9618.67 ± 34.80
Constipation C13D1-3.47 ± 26.8410.48 ± 35.95
Constipation C13D22-3.25 ± 28.6811.11 ± 39.91
Constipation C14D1-8.55 ± 25.0411.11 ± 36.44
Constipation C14D22-3.12 ± 30.953.51 ± 33.14
Constipation C15D1-8.57 ± 30.626.17 ± 32.08
Constipation C15D22-6.67 ± 25.373.92 ± 35.12
Constipation C16D1-5.71 ± 24.907.58 ± 36.99
Constipation C16D22-3.45 ± 27.2314.29 ± 40.75
Constipation C17D1-5.56 ± 27.801.85 ± 29.09
Constipation C17D22-7.25 ± 26.51—
Constipation C18D1-8.64 ± 23.7410.42 ± 33.82
Constipation C18D22-1.59 ± 24.676.67 ± 37.84
Constipation C19D1-2.90 ± 28.2715.56 ± 37.52
Constipation C19D22-5.00 ± 22.3618.18 ± 37.61
Constipation C20D1-2.90 ± 24.4411.11 ± 34.88
Constipation C20D22-7.41 ± 26.953.33 ± 29.19
Constipation C21D1-3.33 ± 26.2714.29 ± 33.88
Constipation C21D220.00 ± 29.24—
Constipation C22D1-6.67 ± 25.822.78 ± 30.01
Constipation C22D22-6.06 ± 29.13—
Constipation C23D1-4.17 ± 26.8717.95 ± 35.00
Constipation C23D22-3.03 ± 17.98—
Constipation C24D1-9.52 ± 27.51—
Constipation C25D12.78 ± 30.01—
Constipation C25D22-3.03 ± 31.46—
Constipation C26D1-5.13 ± 32.90—
Constipation C27D10.00 ± 33.33—
Constipation C28D1-5.56 ± 31.25—
Constipation 30 Day Follow up0.00 ± 32.142.56 ± 34.15
Constipation 90 Day Follow up-5.43 ± 33.861.20 ± 30.11
Diarrhoea Baseline7.91 ± 17.2510.59 ± 19.94
Diarrhoea C1D224.90 ± 23.052.86 ± 24.01
Diarrhoea C2D16.28 ± 26.032.96 ± 22.52
Diarrhoea C2D224.67 ± 24.740.92 ± 22.06
Diarrhoea C3D12.11 ± 22.391.18 ± 24.99
Diarrhoea C3D222.19 ± 24.161.57 ± 24.91
Diarrhoea C4D1-0.20 ± 22.201.02 ± 24.12
Diarrhoea C4D221.90 ± 23.49-0.78 ± 24.91
Diarrhoea C5D13.58 ± 24.55-0.92 ± 25.44
Diarrhoea C5D220.30 ± 20.84-4.31 ± 22.64
Diarrhoea C6D1-2.17 ± 22.48-1.37 ± 24.01
Diarrhoea C6D22-3.24 ± 17.16-1.77 ± 23.63
Diarrhoea C7D1-3.51 ± 20.50-2.04 ± 24.32
Diarrhoea C7D220.41 ± 22.04-7.66 ± 23.11
Diarrhoea C8D1-2.08 ± 20.78-2.81 ± 22.81
Diarrhoea C8D22-5.09 ± 22.14-2.05 ± 22.73
Diarrhoea C9D1-2.22 ± 26.47-2.69 ± 18.40
Diarrhoea C9D22-5.00 ± 20.19-3.03 ± 22.47
Diarrhoea C10D1-5.05 ± 24.97-1.79 ± 19.51
Diarrhoea C10D22-2.92 ± 24.62-1.55 ± 21.77
Diarrhoea C11D1-4.76 ± 26.000.72 ± 22.76
Diarrhoea C11D22-4.55 ± 18.46-2.15 ± 24.24
Diarrhoea C12D10.00 ± 23.57-3.25 ± 19.44
Diarrhoea C12D22-1.75 ± 20.43-4.00 ± 20.00
Diarrhoea C13D1-3.47 ± 30.932.86 ± 27.26
Diarrhoea C13D22-4.07 ± 23.804.76 ± 19.11
Diarrhoea C14D1-1.71 ± 22.884.44 ± 29.99
Diarrhoea C14D22-3.13 ± 21.351.75 ± 26.00
Diarrhoea C15D1-4.76 ± 23.07-3.70 ± 21.35
Diarrhoea C15D22-3.33 ± 20.250.00 ± 16.67
Diarrhoea C16D1-6.67 ± 27.773.03 ± 32.38
Diarrhoea C16D220.00 ± 25.20-4.76 ± 17.82
Diarrhoea C17D1-6.67 ± 26.84-3.70 ± 19.43
Diarrhoea C17D22-1.45 ± 23.52—
Diarrhoea C18D1-4.94 ± 23.94-2.08 ± 25.73
Diarrhoea C18D224.76 ± 33.810.00 ± 15.71
Diarrhoea C19D1-1.45 ± 32.530.00 ± 25.20
Diarrhoea C19D22-3.33 ± 21.360.00 ± 14.91
Diarrhoea C20D1-4.35 ± 25.23-2.22 ± 23.46
Diarrhoea C20D22-5.56 ± 20.613.33 ± 10.54
Diarrhoea C21D1-5.00 ± 24.847.14 ± 19.30
Diarrhoea C21D22-4.76 ± 22.10—
Diarrhoea C22D1-8.89 ± 23.46-5.56 ± 23.92
Diarrhoea C22D22-12.12 ± 22.47—
Diarrhoea C23D1-8.33 ± 22.77-5.13 ± 22.96
Diarrhoea C23D22-6.06 ± 25.03—
Diarrhoea C24D1-11.90 ± 24.83—
Diarrhoea C25D1-16.67 ± 26.59—
Diarrhoea C25D22-12.12 ± 22.47—
Diarrhoea C26D1-15.38 ± 25.88—
Diarrhoea C27D1-9.09 ± 21.56—
Diarrhoea C28D1-11.11 ± 21.71—
Diarrhoea 30 Day Follow up3.24 ± 24.493.66 ± 20.76
Diarrhoea 90 Day Follow up3.88 ± 26.779.24 ± 30.49
Financial Difficulties Baseline19.58 ± 28.8918.86 ± 27.38
Financial Difficulties C1D220.38 ± 24.62-0.48 ± 21.75
Financial Difficulties C2D1-1.45 ± 21.86-1.93 ± 24.01
Financial Difficulties C2D22-0.67 ± 20.96-1.84 ± 23.76
Financial Difficulties C3D1-0.88 ± 22.86-1.85 ± 24.26
Financial Difficulties C3D220.00 ± 21.36-1.12 ± 22.06
Financial Difficulties C4D1-2.55 ± 20.51-3.07 ± 22.77
Financial Difficulties C4D22-1.90 ± 26.41-0.78 ± 20.26
Financial Difficulties C5D10.67 ± 27.25-0.23 ± 26.79
Financial Difficulties C5D222.10 ± 23.04-1.72 ± 26.32
Financial Difficulties C6D1-1.63 ± 22.932.73 ± 25.92
Financial Difficulties C6D22-2.27 ± 21.520.00 ± 26.32
Financial Difficulties C7D1-1.46 ± 24.040.68 ± 23.92
Financial Difficulties C7D22-1.65 ± 22.91-2.70 ± 28.00
Financial Difficulties C8D10.42 ± 24.590.80 ± 26.02
Financial Difficulties C8D22-1.39 ± 24.671.54 ± 27.28
Financial Difficulties C9D1-1.33 ± 23.53-1.08 ± 27.64
Financial Difficulties C9D22-1.11 ± 28.101.82 ± 32.34
Financial Difficulties C10D1-1.01 ± 26.134.76 ± 31.42
Financial Difficulties C10D22-2.92 ± 26.193.88 ± 33.50
Financial Difficulties C11D1-3.17 ± 28.530.72 ± 31.02
Financial Difficulties C11D22-2.27 ± 31.666.45 ± 23.44
Financial Difficulties C12D1-1.26 ± 30.645.69 ± 23.45
Financial Difficulties C12D22-2.63 ± 30.392.67 ± 25.31
Financial Difficulties C13D1-2.78 ± 27.363.81 ± 22.54
Financial Difficulties C13D220.81 ± 30.27-4.76 ± 26.43
Financial Difficulties C14D10.85 ± 22.285.56 ± 26.38
Financial Difficulties C14D220.00 ± 23.95-5.26 ± 27.81
Financial Difficulties C15D1-5.71 ± 28.576.17 ± 30.71
Financial Difficulties C15D22-5.56 ± 26.38-1.96 ± 27.56
Financial Difficulties C16D1-1.90 ± 24.181.52 ± 26.18
Financial Difficulties C16D22-1.15 ± 28.842.38 ± 27.62
Financial Difficulties C17D1-1.11 ± 25.501.85 ± 24.18
Financial Difficulties C17D225.80 ± 16.37—
Financial Difficulties C18D11.23 ± 17.252.08 ± 25.73
Financial Difficulties C18D220.00 ± 14.913.33 ± 24.60
Financial Difficulties C19D10.00 ± 17.418.89 ± 26.63
Financial Difficulties C19D225.00 ± 16.316.06 ± 32.72
Financial Difficulties C20D10.00 ± 17.414.44 ± 24.77
Financial Difficulties C20D223.70 ± 19.436.67 ± 34.43
Financial Difficulties C21D11.67 ± 22.8811.90 ± 28.06
Financial Difficulties C21D22-7.14 ± 19.30—
Financial Difficulties C22D1-2.22 ± 19.792.78 ± 26.43
Financial Difficulties C22D220.00 ± 25.82—
Financial Difficulties C23D1-2.08 ± 19.120.00 ± 23.57
Financial Difficulties C23D22-6.06 ± 20.10—
Financial Difficulties C24D1-4.76 ± 22.10—
Financial Difficulties C25D1-5.56 ± 19.25—
Financial Difficulties C25D22-6.06 ± 25.03—
Financial Difficulties C26D1-5.13 ± 22.96—
Financial Difficulties C27D1-3.03 ± 23.35—
Financial Difficulties C28D1-2.78 ± 22.29—
Financial Difficulties 30 Day Follow up4.17 ± 26.795.13 ± 26.26
Financial Difficulties 90 Day Follow up7.75 ± 24.354.02 ± 31.41
SecondaryChange From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire

The EORTC-QLQ-OG25 consists of a 25-item instrument that evaluates gastric and GEJ cancer-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion. This module consists of 6 scales: dysphagia (3 items), eating restrictions (4 items), reflux (2 items), odynophagia (2 items), pain and discomfort (2 items) and anxiety (2 items), as well as 10 single items: eating in front of others, dry mouth, trouble with taste, body image, trouble swallowing saliva, choked when swallowing, trouble with coughing, trouble talking, weight loss and hair loss. All questions have four response alternatives (1:not at all; 2:a little, 3:quite a bit, 4:very much). Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 For symptom scales/items, higher scores indicate worse symptoms.

Time frame:
Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Reported as:
Mean · unit on a scale
Change From Baseline in HRQoL Measured by the QLQ-OG25 Questionnaire
unit on a scalemFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Dysphagia Baseline18.50 ± 24.3920.02 ± 26.71
Dysphagia C1D222.90 ± 21.18-1.66 ± 22.31
Dysphagia C2D1-3.83 ± 23.11-7.92 ± 25.87
Dysphagia C2D22-4.00 ± 22.34-8.46 ± 23.70
Dysphagia C3D1-8.30 ± 23.64-8.45 ± 24.83
Dysphagia C3D22-4.02 ± 23.60-9.16 ± 26.55
Dysphagia C4D1-6.64 ± 23.49-8.70 ± 23.49
Dysphagia C4D22-2.82 ± 22.11-7.26 ± 24.74
Dysphagia C5D1-6.31 ± 22.64-8.02 ± 24.60
Dysphagia C5D22-4.85 ± 21.84-7.25 ± 22.94
Dysphagia C6D1-5.37 ± 20.46-5.42 ± 20.34
Dysphagia C6D22-5.07 ± 20.45-7.61 ± 21.28
Dysphagia C7D1-6.88 ± 19.66-6.35 ± 20.49
Dysphagia C7D22-6.04 ± 20.49-8.07 ± 20.73
Dysphagia C8D1-3.89 ± 18.38-5.62 ± 16.02
Dysphagia C8D22-5.63 ± 17.90-5.64 ± 20.42
Dysphagia C9D1-6.67 ± 17.62-6.81 ± 18.80
Dysphagia C9D22-5.93 ± 18.35-3.03 ± 19.65
Dysphagia C10D1-5.56 ± 18.92-4.76 ± 19.40
Dysphagia C10D22-8.38 ± 17.73-3.10 ± 20.19
Dysphagia C11D1-6.53 ± 20.32-0.24 ± 23.13
Dysphagia C11D22-8.59 ± 19.59-1.08 ± 10.48
Dysphagia C12D1-4.19 ± 16.19-4.34 ± 18.90
Dysphagia C12D22-6.61 ± 19.15-5.33 ± 14.74
Dysphagia C13D1-6.25 ± 18.47-4.76 ± 17.93
Dysphagia C13D22-4.72 ± 16.28-6.88 ± 24.21
Dysphagia C14D1-4.27 ± 12.39-5.56 ± 20.37
Dysphagia C14D22-4.17 ± 13.16-7.02 ± 25.45
Dysphagia C15D1-2.22 ± 12.58-5.76 ± 19.58
Dysphagia C15D22-4.98 ± 14.72-6.54 ± 27.23
Dysphagia C16D1-4.44 ± 15.29-4.55 ± 26.49
Dysphagia C16D22-2.30 ± 15.82-8.73 ± 28.97
Dysphagia C17D1-2.22 ± 15.82-6.79 ± 24.74
Dysphagia C17D22-4.35 ± 18.87—
Dysphagia C18D1-5.76 ± 15.83-7.64 ± 23.21
Dysphagia C18D22-6.11 ± 14.18-6.67 ± 16.73
Dysphagia C19D1-3.38 ± 14.38-2.22 ± 16.90
Dysphagia C19D22-3.89 ± 10.37-4.04 ± 16.68
Dysphagia C20D1-4.35 ± 11.96-3.70 ± 12.36
Dysphagia C20D22-6.17 ± 14.87-5.56 ± 15.04
Dysphagia C21D1-3.89 ± 10.37-4.76 ± 12.87
Dysphagia C21D22-4.76 ± 18.34—
Dysphagia C22D1-3.70 ± 12.36-5.56 ± 13.81
Dysphagia C22D22-2.22 ± 26.60—
Dysphagia C23D1-4.44 ± 18.69-4.27 ± 14.73
Dysphagia C23D22-7.07 ± 16.68—
Dysphagia C24D1-3.17 ± 19.21—
Dysphagia C25D1-4.63 ± 10.00—
Dysphagia C25D220.00 ± 12.17—
Dysphagia C26D1-1.71 ± 14.23—
Dysphagia C27D11.01 ± 12.62—
Dysphagia C28D10.00 ± 12.54—
Dysphagia 30 day follow-up0.93 ± 21.65-5.93 ± 28.47
Dysphagia 90 day follow-up-2.20 ± 25.56-5.42 ± 34.62
Eating restrictions Baseline30.54 ± 29.0533.01 ± 30.26
Eating restrictions C1D224.40 ± 22.82-1.32 ± 23.11
Eating restrictions C2D1-3.32 ± 27.60-9.94 ± 29.44
Eating restrictions C2D22-5.00 ± 26.41-7.92 ± 30.90
Eating restrictions C3D1-8.77 ± 27.65-13.52 ± 28.28
Eating restrictions C3D22-0.38 ± 27.39-10.98 ± 29.80
Eating restrictions C4D1-6.41 ± 29.50-13.15 ± 28.12
Eating restrictions C4D22-1.09 ± 28.26-10.96 ± 28.79
Eating restrictions C5D1-4.84 ± 27.80-13.43 ± 30.02
Eating restrictions C5D22-3.86 ± 29.62-11.09 ± 28.33
Eating restrictions C6D1-7.79 ± 26.48-9.92 ± 27.41
Eating restrictions C6D22-8.25 ± 27.94-14.67 ± 26.99
Eating restrictions C7D1-9.14 ± 26.63-12.16 ± 24.29
Eating restrictions C7D22-8.13 ± 28.41-14.16 ± 25.26
Eating restrictions C8D1-8.02 ± 21.72-10.60 ± 23.68
Eating restrictions C8D22-8.92 ± 23.41-10.13 ± 26.62
Eating restrictions C9D1-10.89 ± 24.12-12.63 ± 24.78
Eating restrictions C9D22-5.97 ± 26.80-7.73 ± 25.60
Eating restrictions C10D1-7.45 ± 25.20-9.97 ± 25.45
Eating restrictions C10D22-7.60 ± 25.11-5.81 ± 29.07
Eating restrictions C11D1-10.05 ± 24.05-6.16 ± 28.57
Eating restrictions C11D22-8.33 ± 23.23-5.38 ± 20.25
Eating restrictions C12D1-7.39 ± 21.10-7.32 ± 24.94
Eating restrictions C12D22-4.95 ± 20.64-10.67 ± 20.91
Eating restrictions C13D1-7.47 ± 20.72-9.52 ± 25.26
Eating restrictions C13D22-4.17 ± 19.06-7.94 ± 30.79
Eating restrictions C14D1-6.84 ± 22.45-8.61 ± 28.91
Eating restrictions C14D22-7.29 ± 21.77-8.33 ± 28.87
Eating restrictions C15D1-1.90 ± 20.32-6.17 ± 30.97
Eating restrictions C15D22-5.17 ± 18.56-12.75 ± 35.49
Eating restrictions C16D1-6.19 ± 18.89-5.68 ± 36.95
Eating restrictions C16D22-2.30 ± 26.72-10.12 ± 37.15
Eating restrictions C17D1-5.56 ± 16.86-13.89 ± 30.92
Eating restrictions C17D22-2.17 ± 17.63—
Eating restrictions C18D1-6.17 ± 17.54-12.50 ± 31.77
Eating restrictions C18D22-5.00 ± 15.86-15.00 ± 23.17
Eating restrictions C19D1-5.80 ± 13.63-8.89 ± 26.81
Eating restrictions C19D22-3.33 ± 15.63-7.58 ± 20.23
Eating restrictions C20D1-2.17 ± 21.35-10.00 ± 21.87
Eating restrictions C20D22-4.63 ± 17.90-10.00 ± 19.16
Eating restrictions C21D1-0.83 ± 15.74-11.31 ± 20.57
Eating restrictions C21D22-3.57 ± 12.10—
Eating restrictions C22D1-5.00 ± 12.52-9.72 ± 25.33
Eating restrictions C22D22-2.50 ± 18.02—
Eating restrictions C23D1-6.11 ± 11.12-8.97 ± 24.64
Eating restrictions C23D22-4.55 ± 14.12—
Eating restrictions C24D10.00 ± 19.88—
Eating restrictions C25D1-4.86 ± 13.51—
Eating restrictions C25D22-0.76 ± 13.15—
Eating restrictions C26D1-4.49 ± 11.59—
Eating restrictions C27D1-6.06 ± 10.60—
Eating restrictions C28D1-4.17 ± 14.86—
Eating restrictions 30 day follow up2.31 ± 25.03-5.46 ± 33.57
Eating restrictions 90 day follow up-5.62 ± 30.80-5.08 ± 38.53
Reflux Baseline17.64 ± 24.4316.60 ± 24.00
Reflux C1D22-1.70 ± 21.61-1.28 ± 21.70
Reflux C2D1-2.99 ± 24.32-5.31 ± 26.20
Reflux C2D22-4.56 ± 23.00-5.00 ± 23.43
Reflux C3D1-5.61 ± 23.71-6.46 ± 23.10
Reflux C3D22-4.39 ± 21.16-5.86 ± 21.19
Reflux C4D1-5.52 ± 22.18-5.28 ± 20.95
Reflux C4D22-2.46 ± 21.18-5.64 ± 20.49
Reflux C5D1-4.95 ± 22.46-3.24 ± 22.92
Reflux C5D22-2.88 ± 21.76-2.75 ± 22.72
Reflux C6D1-5.87 ± 23.66-1.38 ± 20.82
Reflux C6D22-4.53 ± 20.50-1.81 ± 20.44
Reflux C7D1-4.13 ± 19.741.36 ± 18.64
Reflux C7D22-5.14 ± 21.99-1.14 ± 16.97
Reflux C8D1-5.63 ± 21.370.41 ± 14.19
Reflux C8D22-6.34 ± 22.951.03 ± 18.13
Reflux C9D1-6.00 ± 23.19-0.81 ± 16.65
Reflux C9D22-2.22 ± 18.271.82 ± 14.58
Reflux C10D1-4.80 ± 23.160.30 ± 17.26
Reflux C10D22-6.43 ± 20.115.04 ± 19.43
Reflux C11D1-7.41 ± 21.547.97 ± 24.02
Reflux C11D22-6.82 ± 17.367.53 ± 21.45
Reflux C12D1-4.40 ± 19.388.13 ± 24.75
Reflux C12D22-5.86 ± 21.952.67 ± 19.65
Reflux C13D1-4.17 ± 20.484.76 ± 21.23
Reflux C13D22-2.08 ± 18.945.56 ± 13.26
Reflux C14D1-1.71 ± 21.90-0.56 ± 15.46
Reflux C14D22-5.73 ± 21.007.02 ± 13.96
Reflux C15D1-0.95 ± 14.542.47 ± 21.03
Reflux C15D22-4.60 ± 19.362.94 ± 15.85
Reflux C16D1-3.33 ± 17.996.06 ± 22.74
Reflux C16D22-8.62 ± 21.657.14 ± 28.28
Reflux C17D1-1.11 ± 21.861.85 ± 20.52
Reflux C17D22-1.45 ± 21.27—
Reflux C18D1-4.32 ± 20.46-3.13 ± 17.45
Reflux C18D220.83 ± 22.600.00 ± 23.57
Reflux C19D1-0.72 ± 15.47-1.11 ± 20.38
Reflux C19D22-1.67 ± 14.203.03 ± 14.56
Reflux C20D10.00 ± 15.08-3.33 ± 14.36
Reflux C20D22-2.78 ± 15.391.67 ± 14.59
Reflux C21D10.00 ± 9.37-1.19 ± 12.17
Reflux C21D220.00 ± 11.32—
Reflux C22D10.00 ± 19.92-6.94 ± 16.60
Reflux C22D22-6.67 ± 19.56—
Reflux C23D1-5.56 ± 15.000.00 ± 19.25
Reflux C23D22-6.06 ± 18.67—
Reflux C24D1-4.76 ± 16.57—
Reflux C25D1-5.56 ± 19.25—
Reflux C25D22-4.55 ± 15.08—
Reflux C26D1-1.28 ± 17.30—
Reflux C27D10.00 ± 14.91—
Reflux C28D10.00 ± 12.31—
Reflux 30 day follow up-1.85 ± 26.32-2.96 ± 26.63
Reflux 90 day follow up-0.78 ± 24.911.02 ± 26.49
Odynophagia Baseline22.18 ± 25.9622.44 ± 26.60
Odynophagia C1D22-2.37 ± 24.22-5.69 ± 22.72
Odynophagia C2D1-4.77 ± 24.64-9.19 ± 24.94
Odynophagia C2D22-6.22 ± 24.62-9.35 ± 25.05
Odynophagia C3D1-9.39 ± 24.63-11.39 ± 24.00
Odynophagia C3D22-6.36 ± 22.77-12.50 ± 23.56
Odynophagia C4D1-9.66 ± 24.84-11.18 ± 23.26
Odynophagia C4D22-3.69 ± 25.67-9.19 ± 22.29
Odynophagia C5D1-4.73 ± 23.49-11.23 ± 23.14
Odynophagia C5D22-4.85 ± 26.17-11.01 ± 23.87
Odynophagia C6D1-7.92 ± 20.24-8.13 ± 20.98
Odynophagia C6D22-8.41 ± 22.49-12.32 ± 21.52
Odynophagia C7D1-9.44 ± 21.92-7.99 ± 19.77
Odynophagia C7D22-8.23 ± 22.99-7.31 ± 18.84
Odynophagia C8D1-5.21 ± 20.81-6.58 ± 16.39
Odynophagia C8D22-8.69 ± 22.16-7.44 ± 19.99
Odynophagia C9D1-8.67 ± 20.20-8.06 ± 20.63
Odynophagia C9D22-5.56 ± 20.74-2.42 ± 19.36
Odynophagia C10D1-6.31 ± 18.89-4.17 ± 17.48
Odynophagia C10D22-4.09 ± 18.44-3.49 ± 18.74
Odynophagia C11D1-5.56 ± 17.96-2.54 ± 16.84
Odynophagia C11D22-3.41 ± 14.190.54 ± 11.77
Odynophagia C12D1-4.40 ± 20.45-1.22 ± 15.09
Odynophagia C12D22-2.25 ± 17.64-2.00 ± 17.56
Odynophagia C13D1-3.82 ± 16.93-3.33 ± 13.89
Odynophagia C13D22-4.17 ± 18.780.79 ± 15.34
Odynophagia C14D1-2.56 ± 23.43-0.00 ± 13.13
Odynophagia C14D22-5.73 ± 15.03-1.75 ± 15.61
Odynophagia C15D1-1.43 ± 15.852.47 ± 18.89
Odynophagia C15D22-1.72 ± 16.87-1.96 ± 18.52
Odynophagia C16D1-3.81 ± 13.461.52 ± 18.48
Odynophagia C16D22-4.02 ± 15.211.19 ± 21.15
Odynophagia C17D1-4.44 ± 16.34-0.93 ± 12.09
Odynophagia C17D221.45 ± 25.08—
Odynophagia C18D1-5.56 ± 16.67-1.04 ± 14.23
Odynophagia C18D22-2.50 ± 13.55-5.00 ± 13.72
Odynophagia C19D1-5.80 ± 13.86-2.22 ± 12.39
Odynophagia C19D22-5.00 ± 13.36-3.03 ± 17.98
Odynophagia C20D1-0.72 ± 25.37-5.56 ± 16.27
Odynophagia C20D22-6.48 ± 14.160.00 ± 15.71
Odynophagia C21D1-3.33 ± 8.72-3.57 ± 13.36
Odynophagia C21D22-1.19 ± 10.26—
Odynophagia C22D1-2.22 ± 10.67-2.78 ± 9.62
Odynophagia C22D220.00 ± 13.61—
Odynophagia C23D1-4.44 ± 9.89-5.13 ± 8.01
Odynophagia C23D220.00 ± 14.91—
Odynophagia C24D11.19 ± 21.15—
Odynophagia C25D1-1.39 ± 4.81—
Odynophagia C25D224.55 ± 7.78—
Odynophagia C26D1-1.28 ± 10.68—
Odynophagia C27D1-4.55 ± 10.78—
Odynophagia C28D11.39 ± 4.81—
Odynophagia 30 day follow up-3.01 ± 25.53-4.44 ± 24.20
Odynophagia 90 day follow up-5.62 ± 27.49-3.46 ± 29.01
Pain and Discomfort Baseline27.04 ± 26.6126.39 ± 27.45
Pain and Discomfort C1D22-4.55 ± 21.78-3.45 ± 23.17
Pain and Discomfort C2D1-4.94 ± 26.72-8.37 ± 28.25
Pain and Discomfort C2D22-8.00 ± 25.01-8.89 ± 26.04
Pain and Discomfort C3D1-9.56 ± 24.26-8.50 ± 23.48
Pain and Discomfort C3D22-6.14 ± 23.93-8.67 ± 24.86
Pain and Discomfort C4D1-9.76 ± 24.30-8.70 ± 23.13
Pain and Discomfort C4D22-6.56 ± 21.70-8.79 ± 23.93
Pain and Discomfort C5D1-5.29 ± 22.84-8.68 ± 24.14
Pain and Discomfort C5D22-7.42 ± 26.58-8.99 ± 22.44
Pain and Discomfort C6D1-7.51 ± 23.77-5.79 ± 23.64
Pain and Discomfort C6D22-9.87 ± 26.24-12.68 ± 24.51
Pain and Discomfort C7D1-8.41 ± 23.05-8.50 ± 21.30
Pain and Discomfort C7D22-9.67 ± 21.55-8.68 ± 20.43
Pain and Discomfort C8D1-5.42 ± 24.42-7.82 ± 23.29
Pain and Discomfort C8D22-10.09 ± 23.48-9.23 ± 23.39
Pain and Discomfort C9D1-10.00 ± 22.26-7.53 ± 22.11
Pain and Discomfort C9D22-6.94 ± 22.82-7.27 ± 21.93
Pain and Discomfort C10D1-10.35 ± 22.22-7.14 ± 19.81
Pain and Discomfort C10D22-6.14 ± 22.85-3.49 ± 21.07
Pain and Discomfort C11D1-8.47 ± 19.37-0.72 ± 20.47
Pain and Discomfort C11D22-7.95 ± 19.52-2.15 ± 17.07
Pain and Discomfort C12D1-4.40 ± 20.71-1.63 ± 21.67
Pain and Discomfort C12D22-4.95 ± 19.98-1.33 ± 19.20
Pain and Discomfort C13D1-4.86 ± 21.18-2.38 ± 21.44
Pain and Discomfort C13D22-4.58 ± 22.320.79 ± 23.26
Pain and Discomfort C14D1-2.99 ± 22.58-1.67 ± 21.15
Pain and Discomfort C14D22-9.38 ± 17.42-5.26 ± 20.07
Pain and Discomfort C15D1-1.90 ± 24.51-1.23 ± 24.43
Pain and Discomfort C15D22-6.32 ± 24.16-2.94 ± 25.16
Pain and Discomfort C16D1-7.14 ± 25.34-3.03 ± 20.98
Pain and Discomfort C16D22-8.62 ± 22.55-3.57 ± 23.73
Pain and Discomfort C17D1-3.89 ± 22.611.85 ± 18.86
Pain and Discomfort C17D22-4.35 ± 21.45—
Pain and Discomfort C18D1-8.02 ± 22.35-4.17 ± 20.64
Pain and Discomfort C18D22-8.33 ± 22.62-6.67 ± 11.65
Pain and Discomfort C19D1-13.77 ± 18.57-6.67 ± 23.40
Pain and Discomfort C19D22-7.50 ± 21.95-4.55 ± 21.20
Pain and Discomfort C20D1-11.59 ± 17.72-7.78 ± 20.77
Pain and Discomfort C20D22-11.11 ± 18.96-5.00 ± 15.81
Pain and Discomfort C21D1-8.33 ± 19.12-10.71 ± 19.18
Pain and Discomfort C21D22-9.52 ± 21.40—
Pain and Discomfort C22D1-13.33 ± 19.11-4.17 ± 16.09
Pain and Discomfort C22D22-13.33 ± 21.94—
Pain and Discomfort C23D1-14.44 ± 18.76-7.69 ± 21.10
Pain and Discomfort C23D22-10.61 ± 18.67—
Pain and Discomfort C24D1-13.10 ± 19.81—
Pain and Discomfort C25D1-11.11 ± 19.25—
Pain and Discomfort C25D22-10.61 ± 20.10—
Pain and Discomfort C26D1-14.10 ± 20.24—
Pain and Discomfort C27D1-10.61 ± 15.41—
Pain and Discomfort C28D1-6.94 ± 16.60—
Pain and Discomfort 30 day follow up-6.02 ± 29.11-1.85 ± 27.08
Pain and Discomfort 90 day follow up-6.59 ± 30.17-1.83 ± 32.50
Anxiety Baseline51.30 ± 28.9952.92 ± 30.74
Anxiety C1D22-8.33 ± 24.69-6.09 ± 25.60
Anxiety C2D1-10.19 ± 26.31-11.29 ± 29.40
Anxiety C2D22-11.67 ± 24.33-11.85 ± 30.33
Anxiety C3D1-12.63 ± 26.19-13.44 ± 28.71
Anxiety C3D22-9.65 ± 26.48-14.30 ± 27.90
Anxiety C4D1-14.60 ± 24.61-12.63 ± 26.21
Anxiety C4D22-11.34 ± 26.87-12.99 ± 26.97
Anxiety C5D1-12.16 ± 28.61-7.75 ± 28.42
Anxiety C5D22-10.30 ± 29.61-8.12 ± 25.59
Anxiety C6D1-13.39 ± 31.68-9.09 ± 28.22
Anxiety C6D22-11.65 ± 26.59-14.67 ± 25.30
Anxiety C7D1-12.68 ± 28.46-17.18 ± 25.49
Anxiety C7D22-13.79 ± 27.99-15.98 ± 27.84
Anxiety C8D1-11.46 ± 28.51-14.20 ± 25.97
Anxiety C8D22-13.62 ± 26.92-16.92 ± 28.79
Anxiety C9D1-18.22 ± 25.14-15.86 ± 27.06
Anxiety C9D22-16.94 ± 25.76-20.30 ± 26.97
Anxiety C10D1-16.67 ± 25.15-18.15 ± 31.51
Anxiety C10D22-18.71 ± 27.65-13.95 ± 29.08
Anxiety C11D1-18.25 ± 30.78-9.06 ± 24.77
Anxiety C11D22-20.83 ± 27.40-14.52 ± 29.73
Anxiety C12D1-17.30 ± 30.13-10.57 ± 22.59
Anxiety C12D22-13.06 ± 28.64-19.33 ± 29.53
Anxiety C13D1-15.63 ± 29.26-15.24 ± 25.36
Anxiety C13D22-9.58 ± 25.84-10.32 ± 26.07
Anxiety C14D1-13.68 ± 25.33-15.00 ± 24.11
Anxiety C14D22-18.75 ± 28.95-10.53 ± 23.71
Anxiety C15D1-13.33 ± 27.65-16.67 ± 30.66
Anxiety C15D22-14.37 ± 27.72-17.65 ± 33.06
Anxiety C16D1-17.14 ± 31.95-15.91 ± 29.76
Anxiety C16D22-14.94 ± 26.48-20.24 ± 31.47
Anxiety C17D1-12.78 ± 33.53-20.37 ± 29.46
Anxiety C17D22-11.59 ± 22.15—
Anxiety C18D1-14.81 ± 27.48-15.63 ± 25.44
Anxiety C18D22-15.83 ± 24.47-16.67 ± 30.43
Anxiety C19D1-19.57 ± 30.42-21.11 ± 32.41
Anxiety C19D22-10.00 ± 30.78-16.67 ± 29.81
Anxiety C20D1-21.01 ± 28.52-21.11 ± 26.33
Anxiety C20D22-16.67 ± 25.57-18.33 ± 22.84
Anxiety C21D1-19.17 ± 29.75-15.48 ± 33.63
Anxiety C21D22-14.29 ± 21.54—
Anxiety C22D1-18.89 ± 33.25-16.67 ± 26.59
Anxiety C22D22-3.33 ± 42.16—
Anxiety C23D1-22.22 ± 38.14-23.08 ± 29.30
Anxiety C23D22-16.67 ± 29.81—
Anxiety C24D1-20.24 ± 35.91—
Anxiety C25D1-19.44 ± 38.82—
Anxiety C25D22-12.12 ± 38.07—
Anxiety C26D1-21.79 ± 36.25—
Anxiety C27D1-30.30 ± 30.57—
Anxiety C28D1-20.83 ± 33.43—
Anxiety 30 day follow up-3.47 ± 30.25-6.30 ± 33.39
Anxiety 90 day follow up-2.52 ± 31.88-2.44 ± 33.86
Eating in front of others Baseline14.66 ± 25.1115.95 ± 26.85
Eating in front of others C1D22-1.14 ± 25.42-0.64 ± 23.16
Eating in front of others C2D1-1.46 ± 25.57-4.04 ± 23.86
Eating in front of others C2D22-2.00 ± 28.96-3.52 ± 25.28
Eating in front of others C3D1-5.79 ± 25.11-5.27 ± 27.23
Eating in front of others C3D22-2.19 ± 26.21-6.08 ± 26.38
Eating in front of others C4D1-4.93 ± 27.13-7.45 ± 23.86
Eating in front of others C4D22-0.82 ± 25.16-4.99 ± 26.25
Eating in front of others C5D1-3.83 ± 25.94-4.63 ± 25.43
Eating in front of others C5D22-2.42 ± 26.22-4.06 ± 22.14
Eating in front of others C6D1-5.74 ± 22.14-1.93 ± 24.83
Eating in front of others C6D22-2.27 ± 21.52-4.71 ± 23.48
Eating in front of others C7D1-2.36 ± 26.99-4.76 ± 23.93
Eating in front of others C7D22-2.88 ± 20.55-3.65 ± 22.61
Eating in front of others C8D1-1.25 ± 23.98-4.94 ± 18.34
Eating in front of others C8D22-3.29 ± 21.93-3.59 ± 20.52
Eating in front of others C9D1-6.67 ± 19.76-4.84 ± 23.26
Eating in front of others C9D22-2.22 ± 22.85-0.61 ± 27.59
Eating in front of others C10D1-6.06 ± 26.09-2.98 ± 22.27
Eating in front of others C10D22-3.51 ± 21.53-2.33 ± 21.08
Eating in front of others C11D1-6.35 ± 23.84-1.45 ± 22.17
Eating in front of others C11D22-8.33 ± 22.87-2.15 ± 17.07
Eating in front of others C12D1-5.03 ± 20.04-2.44 ± 18.84
Eating in front of others C12D22-9.91 ± 27.06-5.33 ± 18.46
Eating in front of others C13D1-4.17 ± 27.18-3.81 ± 17.66
Eating in front of others C13D22-3.33 ± 21.08-0.00 ± 25.82
Eating in front of others C14D1-4.27 ± 20.49-2.22 ± 21.32
Eating in front of others C14D22-2.08 ± 22.30-3.51 ± 18.90
Eating in front of others C15D1-0.95 ± 18.94-2.47 ± 15.81
Eating in front of others C15D221.15 ± 25.95-1.96 ± 21.96
Eating in front of others C16D1-2.86 ± 18.74-1.52 ± 21.77
Eating in front of others C16D22-2.30 ± 17.66-4.76 ± 17.82
Eating in front of others C17D1-2.22 ± 21.32-3.70 ± 15.71
Eating in front of others C17D22-1.45 ± 23.52—
Eating in front of others C18D1-3.70 ± 16.88-4.17 ± 16.67
Eating in front of others C18D22-3.33 ± 18.42-10.00 ± 16.10
Eating in front of others C19D1-5.80 ± 16.37-4.44 ± 17.21
Eating in front of others C19D22-6.67 ± 17.44-6.06 ± 13.48
Eating in front of others C20D1-4.35 ± 15.26-4.44 ± 17.21
Eating in front of others C20D22-3.70 ± 19.43-6.67 ± 21.08
Eating in Front of Other C21D1-3.33 ± 14.91-7.14 ± 19.30
Eating in front of others C21D22-4.76 ± 17.82—
Eating in front of others C22D1-2.22 ± 15.26-5.56 ± 19.25
Eating in front of others C22D220.00 ± 15.71—
Eating in front of others C23D1-4.44 ± 17.21-2.56 ± 21.35
Eating in front of others C23D22-3.03 ± 10.05—
Eating in front of others C24D1-4.76 ± 17.82—
Eating in front of others C25D1-8.33 ± 15.08—
Eating in front of others C25D22-3.03 ± 17.98—
Eating in front of others C26D1-7.69 ± 19.97—
Eating in front of others C27D1-6.06 ± 20.10—
Eating in front of others C28D1-5.56 ± 19.25—
Eating in front of others 30 day follow up3.24 ± 24.490.37 ± 33.70
Eating in front of others 90 day follow up1.94 ± 25.230.81 ± 34.34
Dry Mouth Baseline21.92 ± 26.9922.70 ± 26.83
Dry Mouth C1D225.68 ± 27.014.33 ± 27.17
Dry Mouth C2D11.78 ± 31.100.45 ± 28.03
Dry Mouth C2D223.56 ± 26.801.11 ± 29.67
Dry Mouth C3D11.05 ± 31.03-1.53 ± 29.68
Dry Mouth C3D224.39 ± 30.851.13 ± 29.46
Dry Mouth C4D1-0.39 ± 30.43-0.62 ± 29.22
Dry Mouth C4D221.09 ± 29.361.57 ± 29.05
Dry Mouth C5D13.15 ± 32.141.16 ± 27.43
Dry Mouth C5D22-1.91 ± 26.87-0.58 ± 25.74
Dry Mouth C6D1-0.87 ± 25.920.28 ± 29.66
Dry Mouth C6D22-3.56 ± 27.97-3.99 ± 25.60
Dry Mouth C7D1-2.06 ± 25.31-2.38 ± 29.21
Dry Mouth C7D22-0.82 ± 29.33-3.65 ± 31.21
Dry Mouth C8D1-0.83 ± 28.05-3.29 ± 29.16
Dry Mouth C8D22-0.94 ± 28.160.51 ± 30.33
Dry Mouth C9D1-0.44 ± 27.67-0.54 ± 30.47
Dry Mouth C9D222.22 ± 29.98-1.21 ± 31.40
Dry Mouth C10D1-0.51 ± 30.66-2.38 ± 28.33
Dry Mouth C10D22-0.58 ± 25.58-0.78 ± 31.28
Dry Mouth C11D11.59 ± 27.06-2.17 ± 27.58
Dry Mouth C11D222.27 ± 24.27-1.08 ± 21.92
Dry Mouth C12D12.52 ± 29.12-0.81 ± 29.33
Dry Mouth C12D220.90 ± 25.442.67 ± 27.08
Dry Mouth C13D12.08 ± 26.10-1.90 ± 29.09
Dry Mouth C13D224.17 ± 25.25-1.59 ± 34.12
Dry Mouth C14D10.00 ± 26.49-4.44 ± 29.99
Dry Mouth C14D220.00 ± 26.77-5.26 ± 31.94
Dry Mouth C15D10.00 ± 29.15-9.88 ± 28.96
Dry Mouth C15D220.00 ± 26.73-13.73 ± 33.46
Dry Mouth C16D1-1.90 ± 27.94-12.12 ± 30.07
Dry Mouth C16D222.30 ± 26.62-7.14 ± 41.71
Dry Mouth C17D15.56 ± 30.43-9.26 ± 31.94
Dry Mouth C17D221.45 ± 27.48—
Dry Mouth C18D1-3.70 ± 23.27-8.33 ± 35.49
Dry Mouth C18D22-1.67 ± 22.88-6.67 ± 30.63
Dry Mouth C19D1-2.90 ± 26.43-2.22 ± 23.46
Dry Mouth C19D22-3.33 ± 18.420.00 ± 29.81
Dry Mouth C20D1-5.80 ± 25.92-4.44 ± 24.77
Dry Mouth C20D22-5.56 ± 23.57-6.67 ± 30.63
Dry Mouth C21D1-10.00 ± 24.42-2.38 ± 27.62
Dry Mouth C21D22-4.76 ± 22.10-11.11 ± 21.71
Dry Mouth C22D1-11.11 ± 24.12-2.56 ± 28.74
Dry Mouth C22D22-10.00 ± 22.50—
Dry Mouth C23D1-13.33 ± 27.60-2.56 ± 28.74
Dry Mouth C23D22-12.12 ± 22.47—
Dry Mouth C24D1-14.29 ± 25.20—
Dry Mouth C25D1-11.11 ± 21.71—
Dry Mouth C25D22-12.12 ± 22.47—
Dry Mouth C26D1-17.95 ± 25.88—
Dry Mouth C27D1-21.21 ± 26.97—
Dry Mouth C28D1-19.44 ± 26.43—
Dry Mouth 30 day follow up5.09 ± 28.895.19 ± 36.69
Dry Mouth 90 Day follow up1.94 ± 30.834.47 ± 33.85
Trouble with taste Baseline12.06 ± 23.3211.54 ± 22.07
Trouble with taste C1D2210.80 ± 29.668.17 ± 27.46
Trouble with taste C2D112.62 ± 29.494.19 ± 28.69
Trouble with taste C2D2215.78 ± 33.6010.56 ± 31.01
Trouble with taste C3D114.56 ± 34.529.35 ± 30.53
Trouble with taste C3D2221.93 ± 31.6613.51 ± 31.31
Trouble with taste C4D117.75 ± 35.4615.94 ± 34.78
Trouble with taste C4D2220.49 ± 32.4816.01 ± 35.10
Trouble with taste C5D119.59 ± 31.8115.05 ± 29.98
Trouble with taste C5D2220.00 ± 28.9816.52 ± 30.71
Trouble with taste C6D112.02 ± 27.4615.70 ± 26.90
Trouble with taste C6D229.71 ± 29.3810.87 ± 28.86
Trouble with taste C7D18.55 ± 24.719.18 ± 23.83
Trouble with taste C7D2210.70 ± 26.7810.50 ± 24.77
Trouble with taste C8D16.25 ± 22.5610.70 ± 22.25
Trouble with taste C8D223.76 ± 22.2211.28 ± 22.26
Trouble with taste C9D13.56 ± 20.9212.37 ± 28.46
Trouble with taste C9D2212.78 ± 28.8511.52 ± 27.38
Trouble with taste C10D17.07 ± 23.768.33 ± 21.32
Trouble with taste C10D227.02 ± 22.489.30 ± 23.37
Trouble with taste C11D16.35 ± 26.007.25 ± 20.98
Trouble with taste C11D224.55 ± 18.468.60 ± 24.29
Trouble with taste C12D16.29 ± 26.208.13 ± 17.92
Trouble with taste C12D2211.71 ± 25.1116.00 ± 27.42
Trouble with taste C13D17.64 ± 20.9010.48 ± 25.27
Trouble with taste C13D2210.00 ± 27.4322.22 ± 30.43
Trouble with taste C14D14.27 ± 24.4014.44 ± 27.24
Trouble with taste C14D229.37 ± 22.7712.28 ± 22.80
Trouble with taste C15D13.81 ± 26.536.17 ± 18.58
Trouble with taste C15D2211.49 ± 28.563.92 ± 20.01
Trouble with taste C16D17.62 ± 21.524.55 ± 18.67
Trouble with taste C16D226.90 ± 24.204.76 ± 22.10
Trouble with taste C17D14.44 ± 24.345.56 ± 20.61
Trouble with taste C17D2211.59 ± 29.49—
Trouble with taste C18D11.23 ± 19.574.17 ± 20.64
Trouble with taste C18D223.33 ± 18.426.67 ± 26.29
Trouble with taste C19D12.90 ± 17.154.44 ± 17.21
Trouble with taste C19D225.00 ± 22.366.06 ± 25.03
Trouble with taste C20D11.45 ± 15.826.67 ± 22.54
Trouble with taste C20D223.70 ± 15.710.00 ± 15.71
Trouble with taste C21D16.67 ± 17.440.00 ± 13.07
Trouble with Taste C21D22-2.38 ± 20.52—
Trouble with taste C22D12.22 ± 15.265.56 ± 23.92
Trouble with taste C22D220.00 ± 15.71—
Trouble with taste C23D12.22 ± 15.265.13 ± 22.96
Trouble with taste C23D226.06 ± 13.48—
Trouble with taste C24D12.38 ± 15.82—
Trouble with taste C25D10.00 ± 20.10—
Trouble with taste C25D223.03 ± 17.98—
Trouble with taste C26D12.56 ± 16.45—
Trouble with taste C27D10.00 ± 14.91—
Trouble with taste C28D12.78 ± 22.29—
Trouble with taste 30 day follow up12.96 ± 27.1515.93 ± 32.08
Trouble with taste 90 day follow up14.73 ± 28.2913.82 ± 32.69
Body Image Baseline22.57 ± 29.6224.90 ± 30.80
Body Image C1D223.60 ± 25.06-0.96 ± 26.60
Body Image C2D13.56 ± 26.910.00 ± 31.00
Body Image C2D225.11 ± 26.962.78 ± 30.08
Body Image C3D14.21 ± 25.54-0.51 ± 29.33
Body Image C3D227.46 ± 25.21-0.90 ± 28.02
Body Image C4D11.58 ± 24.07-4.35 ± 28.90
Body Image C4D229.29 ± 27.53-3.41 ± 26.84
Body Image C5D15.63 ± 28.67-3.01 ± 26.42
Body Image C5D225.76 ± 30.91-2.32 ± 34.69
Body Image C6D14.64 ± 31.00-1.93 ± 28.32
Body Image C6D221.62 ± 27.76-4.71 ± 29.06
Body Image C7D1-0.29 ± 29.04-2.72 ± 31.27
Body Image C7D223.70 ± 30.28-5.48 ± 34.25
Body Image C8D1-1.25 ± 28.29-2.88 ± 30.82
Body Image C8D22-0.47 ± 31.11-6.15 ± 29.98
Body Image C9D1-4.44 ± 30.67-8.06 ± 32.33
Body Image C9D22-1.11 ± 32.46-8.48 ± 32.21
Body Image C10D1-1.01 ± 32.54-4.17 ± 33.67
Body Image C10D22-0.58 ± 31.80-10.08 ± 31.32
Body Image C11D1-2.65 ± 31.28-5.07 ± 31.40
Body Image C11D22-7.58 ± 27.72-7.53 ± 33.01
Body Image C12D1-0.63 ± 28.86-7.32 ± 30.29
Body Image C12D220.00 ± 33.33-4.00 ± 26.03
Body Image C13D1-2.08 ± 31.81-5.71 ± 27.40
Body Image C13D22-5.00 ± 28.79-12.70 ± 32.45
Body Image C14D1-4.27 ± 30.76-11.11 ± 33.14
Body Image C14D22-1.04 ± 31.09-12.28 ± 33.72
Body Image C15D1-3.81 ± 27.74-12.35 ± 33.52
Body Image C15D2229.08 ± 8.05-17.65 ± 33.58
Body Image C16D1-5.71 ± 28.57-10.61 ± 37.64
Body Image C16D22-8.05 ± 26.21-14.29 ± 33.88
Body Image C17D10.00 ± 36.09-7.41 ± 26.95
Body Image C17D22-2.90 ± 30.01—
Body Image C18D1-7.41 ± 21.35-4.17 ± 31.91
Body Image C18D22-5.00 ± 27.09-20.00 ± 28.11
Body Image C19D1-1.45 ± 25.58-4.44 ± 30.52
Body Image C19D22-5.00 ± 24.84-12.12 ± 34.23
Body Image C20D1-2.90 ± 28.27-8.89 ± 29.46
Body Image C20D22-3.70 ± 27.75-16.67 ± 32.39
Body Image C21D1-6.67 ± 17.442.38 ± 40.22
Body Image C21D22-4.76 ± 22.10—
Body Image C22D10.00 ± 28.17-13.89 ± 36.12
Body Image C22D22-6.67 ± 30.63—
Body Image C23D1-6.67 ± 22.54-5.13 ± 35.61
Body Image C23D22-6.06 ± 20.10—
Body Image C24D1-4.76 ± 22.10—
Body Image C25D1-8.33 ± 28.87—
Body Image C25D22-9.09 ± 30.15—
Body Image C26D1-5.13 ± 26.69—
Body Image C27D1-12.12 ± 16.82—
Body Image C28D1-11.11 ± 16.41—
Body Image 30 day follow up9.72 ± 28.775.56 ± 31.70
Body Image 90 Day follow up6.98 ± 32.398.94 ± 29.65
Trouble swallowing saliva Baseline7.65 ± 17.369.08 ± 20.93
Trouble swallowing saliva C1D220.95 ± 21.51-2.40 ± 19.65
Trouble swallowing saliva C2D11.46 ± 21.91-3.44 ± 24.57
Trouble swallowing saliva C2D221.56 ± 19.44-2.41 ± 24.16
Trouble swallowing saliva C3D1-0.18 ± 20.72-2.89 ± 22.59
Trouble swallowing saliva C3D223.73 ± 25.02-2.25 ± 21.88
Trouble swallowing saliva C4D1-0.59 ± 21.66-3.11 ± 21.34
Trouble swallowing saliva C4D221.64 ± 23.410.26 ± 21.62
Trouble swallowing saliva C5D13.60 ± 24.01-2.78 ± 19.51
Trouble swallowing saliva C5D222.12 ± 21.31-1.45 ± 21.81
Trouble swallowing saliva C6D1-0.82 ± 18.41-0.55 ± 20.63
Trouble swallowing saliva C6D22-1.29 ± 18.03-1.45 ± 20.32
Trouble swallowing saliva C7D1-1.77 ± 19.33-1.70 ± 18.77
Trouble swallowing saliva C7D22-0.41 ± 20.75-0.91 ± 20.77
Trouble swallowing saliva C8D10.00 ± 19.12-2.47 ± 18.09
Trouble swallowing saliva C8D22-0.47 ± 17.36-3.59 ± 22.14
Trouble swallowing saliva C9D1-0.44 ± 17.75-2.15 ± 19.90
Trouble swallowing saliva C9D220.56 ± 19.88-2.42 ± 20.14
Trouble swallowing saliva C10D1-1.52 ± 21.43-2.38 ± 19.96
Trouble swallowing saliva C10D22-1.17 ± 20.86-0.78 ± 21.19
Trouble swallowing saliva C11D10.00 ± 19.861.45 ± 23.26
Trouble swallowing saliva C11D22-4.55 ± 21.074.30 ± 11.36
Trouble swallowing saliva C12D10.00 ± 14.620.00 ± 21.08
Trouble swallowing saliva C12D22-3.60 ± 21.922.67 ± 16.44
Trouble swallowing saliva C13D1-1.39 ± 22.760.00 ± 22.87
Trouble swallowing saliva C13D220.00 ± 23.870.00 ± 25.82
Trouble swallowing saliva C14D11.71 ± 17.01-3.33 ± 20.25
Trouble swallowing saliva C14D22-2.08 ± 14.51-3.51 ± 24.58
Trouble swallowing saliva C15D1-0.95 ± 15.09-6.17 ± 20.75
Trouble swallowing saliva C15D22-2.30 ± 12.38-5.88 ± 24.25
Trouble swallowing saliva C16D10.95 ± 15.09-3.03 ± 22.79
Trouble swallowing saliva C16D22-1.15 ± 14.04-7.14 ± 26.73
Trouble swallowing saliva C17D11.11 ± 16.34-5.56 ± 23.57
Trouble swallowing saliva C17D220.00 ± 17.41—
Trouble swallowing saliva C18D1-1.23 ± 17.25-6.25 ± 25.00
Trouble swallowing saliva C18D22-1.67 ± 13.133.33 ± 10.54
Trouble swallowing saliva C19D1-1.45 ± 12.220.00 ± 0.00
Trouble swallowing saliva C19D220.00 ± 10.810.00 ± 0.00
Trouble swallowing saliva C20D10.00 ± 10.050.00 ± 0.00
Trouble swallowing saliva C20D220.00 ± 11.433.33 ± 10.54
Trouble swallowing saliva C21D11.67 ± 13.130.00 ± 0.00
Trouble swallowing saliva C21D220.00 ± 13.07—
Trouble swallowing saliva C22D1-4.44 ± 17.210.00 ± 0.00
Trouble swallowing saliva C22D22-6.67 ± 21.08—
Trouble swallowing saliva C23D1-4.44 ± 17.210.00 ± 0.00
Trouble swallowing saliva C23D22-9.09 ± 15.57—
Trouble swallowing saliva C24D1-2.38 ± 15.82—
Trouble swallowing saliva C25D1-8.33 ± 15.08—
Trouble swallowing saliva C25D22-3.03 ± 17.98—
Trouble swallowing saliva C26D1-2.56 ± 21.35—
Trouble swallowing saliva C27D1-3.03 ± 17.98—
Trouble swallowing saliva C28D1-2.78 ± 17.16—
Trouble swallowing saliva 30 Day follow up6.94 ± 24.35-0.37 ± 24.73
Trouble swallowing saliva 90 Day follow up2.33 ± 24.94-1.63 ± 24.51
Choked when swallowing Baseline7.00 ± 18.246.10 ± 15.65
Choked when swallowing C1D221.52 ± 17.75-1.28 ± 16.98
Choked when swallowing C2D1-0.49 ± 17.26-1.05 ± 13.93
Choked when swallowing C2D22-2.67 ± 19.12-1.30 ± 16.29
Choked when swallowing C3D1-1.23 ± 18.90-0.34 ± 15.47
Choked when swallowing C3D222.19 ± 19.81-2.93 ± 16.46
Choked when swallowing C4D1-0.99 ± 17.22-1.86 ± 16.77
Choked when swallowing C4D221.09 ± 18.15-0.26 ± 17.57
Choked when swallowing C5D10.45 ± 18.64-2.08 ± 15.88
Choked when swallowing C5D220.91 ± 18.870.29 ± 18.47
Choked when swallowing C6D1-1.37 ± 17.870.83 ± 17.98
Choked when swallowing C6D22-1.62 ± 16.42-2.90 ± 14.54
Choked when swallowing C7D1-2.95 ± 17.00-2.04 ± 15.00
Choked when swallowing C7D220.41 ± 17.07-1.37 ± 16.14
Choked when swallowing C8D1-0.83 ± 18.350.00 ± 14.91
Choked when swallowing C8D22-1.88 ± 16.80-0.51 ± 15.01
Choked when swallowing C9D1-2.22 ± 14.84-1.61 ± 16.45
Choked when swallowing C9D22-0.56 ± 17.88-0.61 ± 17.56
Choked when swallowing C10D1-0.51 ± 17.04-2.38 ± 17.82
Choked when swallowing C10D22-1.17 ± 16.62-2.33 ± 18.40
Choked when swallowing C11D10.53 ± 15.25-1.45 ± 19.82
Choked when swallowing C11D22-1.52 ± 18.962.15 ± 14.75
Choked when swallowing C12D10.00 ± 16.01-0.81 ± 13.92
Choked when swallowing C12D22-1.80 ± 17.47-1.33 ± 15.15
Choked when swallowing C13D1-0.69 ± 16.110.95 ± 22.12
Choked when swallowing C13D220.83 ± 19.231.59 ± 16.59
Choked when swallowing C14D1-2.56 ± 16.010.00 ± 15.16
Choked when swallowing C14D22-6.25 ± 15.70-1.75 ± 13.49
Choked when swallowing C15D1-0.95 ± 12.75-2.47 ± 12.83
Choked when swallowing C15D22-4.60 ± 11.70-3.92 ± 11.07
Choked when swallowing C16D1-1.90 ± 13.870.00 ± 10.29
Choked when swallowing C16D22-2.30 ± 12.38-2.38 ± 8.91
Choked when swallowing C17D1-2.22 ± 17.36-3.70 ± 10.78
Choked when swallowing C17D22-1.45 ± 21.27—
Choked when swallowing C18D1-2.47 ± 18.320.00 ± 12.17
Choked when swallowing C18D221.67 ± 13.130.00 ± 22.22
Choked when swallowing C19D10.00 ± 17.41-2.22 ± 15.26
Choked when swallowing C19D220.00 ± 10.81-3.03 ± 17.98
Choked when swallowing C20D10.00 ± 10.05-4.44 ± 11.73
Choked when swallowing C20D220.00 ± 11.43-3.33 ± 18.92
Choked when swallowing C21D1-1.67 ± 17.01-4.76 ± 12.10
Choked when swallowing C21D22-4.76 ± 17.82—
Choked when swallowing C22D1-2.22 ± 15.26-2.78 ± 17.16
Choked when swallowing C22D22-10.00 ± 22.50—
Choked when swallowing C23D1-4.44 ± 21.332.56 ± 16.45
Choked when swallowing C23D22-9.09 ± 21.56—
Choked when swallowing C24D1-4.76 ± 22.10—
Choked when swallowing C25D1-8.33 ± 20.72—
Choked when swallowing C25D22-6.06 ± 25.03—
Choked when swallowing C26D1-5.13 ± 22.96—
Choked when swallowing C27D10.00 ± 14.91—
Choked when swallowing C28D10.00 ± 14.21—
Choked when swallowing 30 Day follow up1.39 ± 20.510.00 ± 17.31
Choked when swallowing 90 Day follow up2.71 ± 19.281.63 ± 22.77
Trouble with coughing Baseline12.06 ± 19.6916.73 ± 22.85
Trouble with coughing C1D224.17 ± 23.27-3.04 ± 21.14
Trouble with coughing C2D12.75 ± 23.47-4.19 ± 24.56
Trouble with coughing C2D222.22 ± 20.31-3.70 ± 27.04
Trouble with coughing C3D14.74 ± 26.24-5.78 ± 24.12
Trouble with coughing C3D223.29 ± 24.19-4.28 ± 23.74
Trouble with coughing C4D11.97 ± 23.77-7.04 ± 23.40
Trouble with coughing C4D221.37 ± 18.87-4.20 ± 23.75
Trouble with coughing C5D11.80 ± 20.86-5.32 ± 22.18
Trouble with coughing C5D221.21 ± 20.66-3.48 ± 23.93
Trouble with coughing C6D1-0.82 ± 22.05-3.03 ± 22.77
Trouble with coughing C6D22-0.65 ± 19.79-5.80 ± 22.97
Trouble with coughing C7D10.29 ± 20.65-4.42 ± 19.52
Trouble with coughing C7D22-1.65 ± 18.18-7.31 ± 20.22
Trouble with coughing C8D10.83 ± 21.85-3.29 ± 20.14
Trouble with coughing C8D222.35 ± 18.96-5.64 ± 21.71
Trouble with coughing C9D1-2.22 ± 17.62-1.61 ± 22.93
Trouble with coughing C9D222.22 ± 22.01-1.82 ± 22.61
Trouble with coughing C10D1-1.01 ± 18.46-4.17 ± 22.97
Trouble with coughing C10D220.58 ± 17.24-3.88 ± 25.42
Trouble with coughing C11D10.00 ± 17.96-1.45 ± 26.25
Trouble with coughing C11D22-1.52 ± 16.000.00 ± 22.77
Trouble with coughing C12D1-0.63 ± 16.65-4.88 ± 24.22
Trouble with coughing C12D220.90 ± 12.39-6.67 ± 23.57
Trouble with coughing C13D12.08 ± 17.40-8.57 ± 21.91
Trouble with coughing C13D224.17 ± 15.45-4.76 ± 28.45
Trouble with coughing C14D12.56 ± 16.01-2.22 ± 26.16
Trouble with coughing C14D22-3.12 ± 13.01-7.02 ± 26.24
Trouble with coughing C15D12.86 ± 23.39-1.23 ± 25.29
Trouble with coughing C15D220.00 ± 15.43-7.84 ± 25.08
Trouble with coughing C16D11.90 ± 16.05-9.09 ± 21.04
Trouble with coughing C16D224.60 ± 19.36-9.52 ± 27.51
Trouble with coughing C17D13.33 ± 16.02-3.70 ± 25.28
Trouble with coughing C17D22-1.45 ± 15.82—
Trouble with coughing C18D10.00 ± 16.01-6.25 ± 27.81
Trouble with coughing C18D221.67 ± 13.13-10.00 ± 22.50
Trouble with coughing C19D1-1.45 ± 12.22-4.44 ± 21.33
Trouble with coughing C19D223.33 ± 14.91-6.06 ± 25.03
Trouble with coughing C20D10.00 ± 14.21-4.44 ± 17.21
Trouble with coughing C20D221.85 ± 13.87-6.67 ± 21.08
Trouble with coughing C21D1-3.33 ± 10.260.00 ± 26.15
Trouble with coughing C21D222.38 ± 8.91—
Trouble with coughing C22D1-4.44 ± 11.73-2.78 ± 26.43
Trouble with coughing C22D220.00 ± 15.71—
Trouble with coughing C23D1-2.22 ± 15.260.00 ± 23.57
Trouble with coughing C23D22-6.06 ± 13.48—
Trouble with coughing C24D1-4.76 ± 12.10—
Trouble with coughing C25D1-8.33 ± 15.08—
Trouble with coughing C25D22-3.03 ± 10.05—
Trouble with coughing C26D1-7.69 ± 14.62—
Trouble with coughing C27D1-6.06 ± 13.48—
Trouble with coughing C28D1-8.33 ± 15.08—
Trouble with coughing 30 day follow up-0.93 ± 27.96-5.93 ± 26.24
Trouble with coughing 90 Day follow up2.33 ± 22.75-2.85 ± 21.72
Trouble talking Baseline5.45 ± 14.005.97 ± 15.28
Trouble talking C1D223.03 ± 19.931.60 ± 14.56
Trouble talking C2D10.81 ± 16.28-0.75 ± 15.96
Trouble talking C2D220.89 ± 16.810.93 ± 15.93
Trouble talking C3D1-0.18 ± 15.52-0.34 ± 15.09
Trouble talking C3D220.66 ± 16.930.23 ± 15.31
Trouble talking C4D10.59 ± 16.05-0.21 ± 14.67
Trouble talking C4D222.19 ± 19.04-0.52 ± 17.81
Trouble talking C5D1-0.68 ± 15.291.16 ± 17.81
Trouble talking C5D221.21 ± 16.231.45 ± 19.94
Trouble talking C6D1-0.27 ± 15.741.10 ± 16.63
Trouble talking C6D22-1.62 ± 16.421.09 ± 16.72
Trouble talking C7D1-1.47 ± 17.470.34 ± 14.75
Trouble talking C7D22-1.65 ± 15.720.46 ± 15.21
Trouble talking C8D11.25 ± 20.165.35 ± 17.84
Trouble talking C8D22-1.41 ± 15.363.59 ± 18.75
Trouble talking C9D1-2.67 ± 11.963.23 ± 17.81
Trouble talking C9D22-0.56 ± 15.641.82 ± 13.48
Trouble talking C10D1-1.01 ± 13.032.38 ± 12.48
Trouble talking C10D220.58 ± 13.354.65 ± 18.66
Trouble talking C11D10.53 ± 14.034.35 ± 19.38
Trouble talking C11D22-3.03 ± 14.054.30 ± 22.35
Trouble talking C12D1-0.63 ± 13.852.44 ± 17.30
Trouble talking C12D22-2.70 ± 12.128.00 ± 24.11
Trouble talking C13D1-0.69 ± 14.574.76 ± 21.61
Trouble talking C13D22-0.83 ± 14.106.35 ± 22.65
Trouble talking C14D1-0.85 ± 14.283.33 ± 13.42
Trouble talking C14D22-2.08 ± 11.791.75 ± 7.65
Trouble talking C15D10.00 ± 14.001.23 ± 11.25
Trouble talking C15D220.00 ± 12.60-1.96 ± 8.08
Trouble talking C16D1-1.90 ± 13.871.52 ± 12.50
Trouble talking C16D22-3.45 ± 13.640.00 ± 13.07
Trouble talking C17D11.11 ± 13.790.00 ± 11.43
Trouble talking C17D22-4.35 ± 15.26—
Trouble talking C18D1-2.47 ± 8.900.00 ± 12.17
Trouble talking C18D220.00 ± 10.81-3.33 ± 10.54
Trouble talking C19D1-1.45 ± 6.952.22 ± 15.26
Trouble talking C19D220.00 ± 0.00-3.03 ± 10.05
Trouble talking C20D14.35 ± 23.150.00 ± 12.60
Trouble Talking C20D22-1.85 ± 7.860.00 ± 0.00
Trouble talking C21D1-1.67 ± 7.45-2.38 ± 8.91
Trouble talking C21D220.00 ± 0.00—
Trouble talking C22D1-2.22 ± 15.260.00 ± 14.21
Trouble talking C22D22-3.33 ± 10.540.00 ± 13.61
Trouble talking C23D10.00 ± 12.60—
Trouble talking C23D22-3.03 ± 10.05—
Trouble talking C24D1-4.76 ± 12.10—
Trouble talking C25D1-5.56 ± 12.97—
Trouble talking C25D223.03 ± 23.35—
Trouble talking C26D1-2.56 ± 9.25—
Trouble talking C27D1-3.03 ± 10.05—
Trouble talking C28D1-2.78 ± 9.62—
Trouble talking 30 day follow up1.85 ± 21.592.59 ± 15.98
Trouble talking 90 Day follow up1.16 ± 18.754.88 ± 14.93
Weight loss Baseline29.70 ± 32.4734.24 ± 31.38
Weight loss C1D220.95 ± 28.60-2.72 ± 28.34
Weight loss C2D1-0.65 ± 31.23-7.92 ± 28.33
Weight loss C2D220.00 ± 30.41-6.11 ± 30.41
Weight loss C3D1-2.46 ± 31.14-9.35 ± 30.34
Weight loss C3D22-1.75 ± 31.59-9.46 ± 29.62
Weight loss C4D1-5.72 ± 29.32-13.87 ± 29.71
Weight loss C4D22-2.19 ± 32.84-12.34 ± 29.04
Weight loss C5D1-3.15 ± 35.49-12.04 ± 28.32
Weight loss C5D22-5.76 ± 33.44-13.33 ± 32.08
Weight loss C6D1-6.01 ± 31.79-11.02 ± 30.24
Weight loss C6D22-9.39 ± 34.11-15.58 ± 30.64
Weight loss C7D1-11.80 ± 31.79-15.31 ± 28.38
Weight loss C7D22-8.64 ± 34.47-21.00 ± 31.18
Weight loss C8D1-10.83 ± 31.28-13.58 ± 27.27
Weight loss C8D22-11.27 ± 33.78-14.87 ± 27.66
Weight loss C9D1-15.56 ± 32.11-13.98 ± 25.28
Weight loss C9D22-9.44 ± 34.77-19.39 ± 28.47
Weight loss C10D1-10.61 ± 33.67-16.07 ± 31.78
Weight loss C10D22-11.11 ± 30.43-20.93 ± 30.88
Weight loss C11D1-12.17 ± 34.03-15.94 ± 32.00
Weight loss C11D22-17.42 ± 29.19-17.20 ± 29.65
Weight loss C12D1-10.06 ± 33.71-18.70 ± 28.91
Weight loss C12D22-11.71 ± 27.46-20.00 ± 30.43
Weight loss C13D1-10.42 ± 29.30-21.90 ± 33.28
Weight loss C13D22-10.00 ± 26.37-25.40 ± 23.34
Weight loss C14D1-11.97 ± 25.92-21.11 ± 29.66
Weight loss C14D22-8.33 ± 28.08-26.32 ± 30.59
Weight loss C15D1-6.67 ± 26.57-23.46 ± 34.36
Weight loss C15D22-8.05 ± 26.21-23.53 ± 38.67
Weight loss C16D1-13.33 ± 23.15-18.18 ± 38.11
Weight loss C16D22-8.05 ± 30.41-23.81 ± 27.51
Weight loss C17D1-10.00 ± 26.48-20.37 ± 30.55
Weight loss C17D22-8.70 ± 25.06—
Weight loss C18D1-14.81 ± 23.27-16.67 ± 32.20
Weight loss C18D22-15.00 ± 25.31-30.00 ± 29.19
Weight loss C19D1-17.39 ± 22.18-17.78 ± 33.01
Weight loss C19D22-11.67 ± 29.17-27.27 ± 32.72
Weight loss C20D1-15.94 ± 24.35-17.78 ± 27.79
Weight loss C20D22-14.81 ± 26.13-30.00 ± 33.15
Weight loss C21D1-16.67 ± 25.36-23.81 ± 30.46
Weight loss C21D22-16.67 ± 28.50—
Weight loss C22D1-15.56 ± 27.79-16.67 ± 36.24
Weight loss C22D22-20.00 ± 28.11—
Weight loss C23D1-15.56 ± 24.77-15.38 ± 37.55
Weight loss C23D22-9.09 ± 30.15—
Weight loss C24D1-16.67 ± 28.50—
Weight loss C25D1-11.11 ± 25.95—
Weight loss C25D22-12.12 ± 22.47—
Weight loss C26D1-17.95 ± 22.01—
Weight loss C27D1-24.24 ± 15.57—
Weight loss C28D1-16.67 ± 22.47—
Weight loss 30 day follow up3.24 ± 34.10-9.63 ± 33.98
Weight Loss 90 Day follow up-2.71 ± 37.99-6.91 ± 37.31
Hair loss Baseline15.62 ± 26.5414.14 ± 29.27
Hair loss C1D2211.11 ± 25.384.07 ± 29.05
Hair loss C2D10.88 ± 27.393.10 ± 28.00
Hair loss C2D224.04 ± 32.013.45 ± 24.14
Hair loss C3D18.82 ± 26.352.70 ± 30.81
Hair loss C3D2210.34 ± 25.360.00 ± 27.22
Hair loss C4D19.68 ± 23.087.78 ± 34.67
Hair loss C4D2211.54 ± 22.9811.59 ± 21.58
Hair loss C5D16.17 ± 24.5210.67 ± 26.74
Hair loss C5D2210.53 ± 27.340.00 ± 37.27
Hair loss C6D18.70 ± 25.069.52 ± 28.17
Hair loss C6D224.17 ± 23.964.76 ± 38.91
Hair loss C7D12.22 ± 23.467.84 ± 30.11
Hair loss C7D221.96 ± 18.525.56 ± 37.15
Hair loss C8D15.56 ± 17.150.00 ± 30.86
Hair loss C8D229.09 ± 15.572.78 ± 26.43
Hair loss C9D10.00 ± 14.910.00 ± 36.51
Hair loss C9D2213.33 ± 17.210.00 ± 40.82
Hair loss C10D111.11 ± 28.876.67 ± 40.98
Hair loss C10D2212.50 ± 17.25-9.52 ± 53.45
Hair loss C11D115.15 ± 17.410.00 ± 43.64
Hair loss C11D2212.50 ± 17.254.76 ± 23.00
Hair loss C12D113.33 ± 23.31-5.56 ± 49.07
Hair loss C12D2212.50 ± 35.36-16.67 ± 40.82
Hair loss C13D17.41 ± 14.70—
Hair loss C13D2213.33 ± 18.264.76 ± 29.99
Hair loss C14D19.52 ± 16.276.67 ± 27.89
Hair loss C14D2233.33 ± 40.82—
Hair loss C15D123.81 ± 37.09—
Hair loss C15D2216.67 ± 19.25—
Hair loss C16D113.33 ± 18.26—
Hair loss C16D2216.67 ± 19.25—
Hair loss C17D18.33 ± 31.91—
Hair loss C17D220.00 ± 27.22—
Hair loss C18D10.00 ± 27.22—
Hair loss C19D2241.67 ± 31.91—
Hair loss 30 day follow up-11.11 ± 45.5418.18 ± 22.92
Hair loss 90 day follow up21.43 ± 33.6116.67 ± 25.32
SecondaryChange From Baseline in HRQoL Measured by Global Pain (GP)

The GP instrument is a single assessment of overall pain. Participants were assessed in global pain according to the following response categories: 1= no pain (anymore), 2 = less pain, 3 = no change and 4 = more pain.

Time frame:
Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Reported as:
Mean · units on a scale
Change From Baseline in HRQoL Measured by Global Pain (GP)
units on a scalemFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Baseline2.87 ± 2.672.96 ± 2.74
C1D22-0.55 ± 2.85-0.74 ± 2.32
C2D1-0.75 ± 2.94-0.75 ± 2.98
C2D22-0.67 ± 3.11-1.01 ± 2.70
C3D1-0.87 ± 2.88-0.90 ± 2.70
C3D22-0.62 ± 3.16-0.83 ± 2.60
C4D1-0.86 ± 2.61-0.66 ± 2.81
C4D22-0.51 ± 3.02-0.78 ± 2.55
C5D1-0.53 ± 2.91-0.81 ± 2.91
C5D22-0.54 ± 2.89-0.84 ± 3.00
C6D1-0.63 ± 3.13-0.32 ± 3.33
C6D22-0.68 ± 2.91-0.98 ± 2.52
C7D1-0.46 ± 2.87-0.86 ± 2.88
C7D22-0.31 ± 3.00-1.01 ± 2.60
C8D1-0.69 ± 2.54-0.67 ± 3.17
C8D22-0.79 ± 3.28-1.09 ± 2.30
C9D1-0.71 ± 3.05-1.18 ± 2.04
C9D22-1.02 ± 2.76-1.13 ± 2.71
C10D1-0.54 ± 2.84-0.75 ± 2.91
C10D22-0.50 ± 3.12-0.74 ± 3.09
C11D1-0.38 ± 3.58-0.96 ± 2.16
C11D22-0.59 ± 3.27-0.77 ± 1.89
C12D1-0.30 ± 3.42-0.54 ± 2.81
C12D22-0.14 ± 2.82-0.88 ± 2.17
C13D1-0.79 ± 3.51-0.66 ± 2.52
C13D22-0.63 ± 3.01-1.19 ± 3.23
C14D1-0.21 ± 2.91-0.37 ± 2.46
C14D22-0.44 ± 3.70-0.84 ± 3.34
C15D10.09 ± 3.490.22 ± 3.63
C15D22-0.38 ± 3.81-0.71 ± 3.62
C16D1-0.60 ± 3.91-0.45 ± 3.66
C16D22-0.97 ± 3.23-0.71 ± 2.46
C17D1-0.03 ± 2.94-0.53 ± 2.62
C17D220.22 ± 3.00—
C18D1-0.62 ± 3.11-0.31 ± 2.91
C18D22-1.14 ± 2.87-0.40 ± 2.32
C19D1-1.04 ± 3.24-0.73 ± 2.22
C19D22-0.50 ± 2.33-0.45 ± 2.34
C20D1-0.43 ± 3.260.60 ± 3.07
C20D22-0.17 ± 3.70-0.20 ± 2.74
C21D1-0.50 ± 3.66-0.79 ± 2.36
C21D220.57 ± 2.90—
C22D10.07 ± 3.47-0.42 ± 2.78
C22D220.60 ± 3.24—
C23D11.07 ± 4.13-0.54 ± 2.63
C23D221.27 ± 4.13—
C24D11.43 ± 4.54—
C25D12.33 ± 3.03—
C25D221.45 ± 3.30—
C26D11.08 ± 3.77—
C27D11.55 ± 3.75—
C28D11.42 ± 3.55—
30 day follow up-0.19 ± 2.990.39 ± 3.16
90 Day follow up-0.27 ± 2.940.31 ± 3.12
SecondaryChange From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire

EQ-5D-5L is a standardized instrument for use as a measure of health outcomes consisting of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale for health status.It was developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples.

Time frame:
Baseline, C1D22, D1 and D22 of C2 through C25, C26D1, C27D1,C28D1 30 day follow up, 90 day follow up
Reported as:
Mean · units on a scale
Change From Baseline in HRQoL Measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) Questionnaire
units on a scalemFOLFOX6 + ZolbetuximabmFOLFOX6+ Placebo
Mobility Baseline1.40 ± 0.731.40 ± 0.74
Mobility C1D220.15 ± 0.67-0.01 ± 0.68
Mobility C2D10.09 ± 0.76-0.05 ± 0.77
Mobility C2D220.03 ± 0.76-0.05 ± 0.64
Mobility C3D10.09 ± 0.85-0.02 ± 0.82
Mobility C3D220.21 ± 0.88-0.04 ± 0.70
Mobility C4D10.16 ± 0.940.01 ± 0.76
Mobility C4D220.16 ± 0.900.13 ± 0.82
Mobility C5D10.15 ± 0.890.18 ± 0.80
Mobility C5D220.27 ± 0.960.16 ± 0.81
Mobility C6D10.20 ± 0.820.20 ± 0.72
Mobility C6D220.17 ± 0.900.23 ± 0.69
Mobility C7D10.17 ± 0.900.10 ± 0.63
Mobility C7D220.26 ± 0.910.24 ± 0.72
Mobility C8D10.17 ± 0.780.20 ± 0.68
Mobility C8D220.10 ± 0.610.12 ± 0.67
Mobility C9D10.13 ± 0.780.10 ± 0.65
Mobility C9D220.11 ± 0.820.09 ± 0.62
Mobility C10D10.12 ± 0.850.11 ± 0.87
Mobility C10D220.00 ± 0.730.09 ± 0.75
Mobility C11D10.16 ± 0.880.17 ± 0.74
Mobility C11D220.11 ± 0.830.23 ± 0.56
Mobility C12D10.08 ± 0.760.32 ± 0.72
Mobility C12D220.21 ± 0.810.31 ± 0.74
Mobility C13D10.02 ± 0.730.20 ± 0.68
Mobility C13D220.20 ± 0.680.24 ± 0.77
Mobility C14D10.05 ± 0.720.23 ± 0.73
Mobility C14D220.16 ± 0.810.16 ± 0.69
Mobility C15D10.23 ± 0.840.15 ± 0.66
Mobility C15D220.30 ± 0.750.06 ± 0.56
Mobility C16D10.20 ± 0.830.14 ± 0.64
Mobility C16D220.03 ± 0.680.29 ± 0.73
Mobility C17D10.23 ± 0.860.17 ± 0.51
Mobility C17D220.17 ± 0.83—
Mobility C18D10.15 ± 1.100.19 ± 0.40
Mobility C18D220.05 ± 0.670.20 ± 0.42
Mobility C19D10.09 ± 0.510.27 ± 0.46
Mobility C19D220.20 ± 0.520.27 ± 0.47
Mobility C20D10.13 ± 0.630.13 ± 0.52
Mobility C20D220.17 ± 0.710.10 ± 0.32
Mobility C21D10.15 ± 0.490.07 ± 0.27
Mobility C21D220.14 ± 0.53—
Mobility C22D10.20 ± 0.770.00 ± 0.43
Mobility C22D220.55 ± 0.82—
Mobility C23D10.31 ± 0.700.00 ± 0.41
Mobility C23D220.09 ± 0.54—
Mobility C24D10.14 ± 0.36—
Mobility C25D10.25 ± 0.62—
Mobility C25D220.27 ± 0.47—
Mobility C26D10.23 ± 0.44—
Mobility C27D10.00 ± 0.00—
Mobility C28D10.17 ± 0.39—
Mobility 30 Day follow up0.38 ± 1.110.47 ± 0.99
Mobility 90 Day follow up0.51 ± 1.090.53 ± 0.99
Self-care Baseline1.23 ± 0.571.21 ± 0.56
Self-care C1DD220.11 ± 0.660.07 ± 0.49
Self-care C2D10.08 ± 0.65-0.04 ± 0.52
Self-care C2D220.09 ± 0.77-0.01 ± 0.56
Self-care C3D10.06 ± 0.690.06 ± 0.61
Self-care C3D220.06 ± 0.72-0.01 ± 0.43
Self-care C4D10.08 ± 0.810.03 ± 0.54
Self-care C4D220.05 ± 0.720.03 ± 0.49
Self-care C5D10.10 ± 0.860.05 ± 0.50
Self-care C5D220.16 ± 0.820.09 ± 0.57
Self-care C6D10.07 ± 0.660.10 ± 0.54
Self-care C6D220.07 ± 0.740.05 ± 0.55
Self-care C7D10.11 ± 0.750.11 ± 0.49
Self-care C7D220.01 ± 0.780.04 ± 0.48
Self-care C8D10.09 ± 0.950.10 ± 0.55
Self-care C8D22-0.01 ± 0.640.08 ± 0.62
Self-care C9D10.08 ± 0.870.02 ± 0.46
Self-care C9D22-0.02 ± 0.810.04 ± 0.61
Self-care C10D1-0.03 ± 0.800.11 ± 0.65
Self-care C10D22-0.04 ± 0.800.09 ± 0.48
Self-care C11D10.00 ± 0.930.11 ± 0.43
Self-care C11D22-0.04 ± 0.640.10 ± 0.30
Self-care C12D1-0.04 ± 0.760.20 ± 0.40
Self-care C12D22-0.05 ± 0.730.15 ± 0.37
Self-care C13DD1-0.06 ± 0.760.14 ± 0.43
Self-care C13D22-0.02 ± 0.850.14 ± 0.36
Self-care C14D1-0.08 ± 0.740.10 ± 0.31
Self-care C14D220.03 ± 0.860.16 ± 0.37
Self-care C15D1-0.03 ± 0.790.19 ± 0.40
Self-care C15D22-0.03 ± 0.850.12 ± 0.33
Self-care C16D10.00 ± 0.840.09 ± 0.29
Self-care C16D22-0.10 ± 0.820.07 ± 0.27
Self-care C17D10.03 ± 1.000.00 ± 0.00
Self-care C17D220.13 ± 0.92—
Self-care C18D10.00 ± 0.920.06 ± 0.25
Self-care C18D22-0.10 ± 0.940.10 ± 0.32
Self-care C19D10.04 ± 0.770.20 ± 0.41
Self-care C19D220.20 ± 1.060.09 ± 0.30
Self-care C20D10.09 ± 0.850.13 ± 0.35
Self-care C20D220.06 ± 0.800.00 ± 0.00
Self-care C21D10.10 ± 0.640.14 ± 0.36
Self-care C21D220.29 ± 0.73—
Self-care C22D10.20 ± 0.770.00 ± 0.00
Self-care C22D220.18 ± 0.60—
Self-care C23D10.31 ± 0.870.08 ± 0.28
Self-care C23D220.27 ± 0.79—
Self-care C24D10.21 ± 0.89—
Self-care C25D10.00 ± 0.43—
Self-care C25D220.09 ± 0.54—
Self-care C26D1-0.08 ± 0.49—
Self-care C27D1-0.18 ± 0.40—
Self-care C28D1-0.08 ± 0.51—
Self-Care 30 Day follow up0.21 ± 0.900.30 ± 0.72
Self-care 90 Day follow up0.35 ± 0.900.39 ± 0.78
Usual Activities Baseline1.68 ± 0.971.56 ± 0.88
Usual Activities C1D220.24 ± 0.800.14 ± 0.89
Usual Activities C2D10.08 ± 0.87-0.01 ± 0.82
Usual Activities C2D220.05 ± 0.86-0.01 ± 0.77
Usual Activities C3D10.05 ± 0.910.01 ± 0.82
Usual Activities C3D220.23 ± 0.900.05 ± 0.89
Usual Activities C4D10.06 ± 0.920.04 ± 0.83
Usual Activities C4D220.11 ± 0.850.16 ± 0.80
Usual Activities C5D10.13 ± 0.930.15 ± 0.80
Usual Activities C5D220.17 ± 0.940.18 ± 0.84
Usual Activities C6D10.14 ± 0.940.25 ± 0.84
Usual Activities C6D220.15 ± 1.020.15 ± 0.81
Usual Activities C7D10.15 ± 1.050.12 ± 0.80
Usual Activities C7D220.15 ± 1.100.05 ± 0.76
Usual Activities C8D10.18 ± 0.970.18 ± 0.87
Usual Activities C8D220.03 ± 1.050.09 ± 0.86
Usual Activities C9D10.07 ± 0.960.03 ± 0.75
Usual Activities C9D220.13 ± 0.990.07 ± 0.72
Usual Activities C10D1-0.02 ± 1.000.07 ± 0.95
Usual Activities C10D22-0.02 ± 0.880.09 ± 0.87
Usual Activities C11D1-0.05 ± 0.870.04 ± 0.82
Usual Activities C11D220.09 ± 0.950.23 ± 0.67
Usual Activities C12D1-0.08 ± 1.000.12 ± 0.60
Usual Activities C12D220.00 ± 0.930.23 ± 0.71
Usual Activities C13D10.04 ± 0.820.14 ± 0.81
Usual Activities C13D220.15 ± 0.880.10 ± 0.89
Usual Activities C14D10.03 ± 0.840.27 ± 0.91
Usual Activities C14D220.06 ± 0.760.00 ± 0.88
Usual Activities C15D10.09 ± 0.740.07 ± 0.68
Usual Activities C15D220.13 ± 1.04-0.12 ± 0.86
Usual Activities C16D10.20 ± 1.080.05 ± 0.84
Usual Activities C16D22-0.10 ± 0.720.14 ± 0.86
Usual Activities C17D10.23 ± 0.970.00 ± 0.69
Usual Activities C17D220.26 ± 0.86—
Usual Activities C18D1-0.07 ± 0.680.00 ± 0.37
Usual Activities C18D220.00 ± 0.840.10 ± 0.57
Usual Activities C19D10.13 ± 0.760.13 ± 0.52
Usual Activities C19D220.20 ± 0.770.00 ± 0.45
Usual Activities C20D10.04 ± 0.640.07 ± 0.46
Usual Activities C20D220.11 ± 0.83-0.10 ± 0.32
Usual Activities C21D10.10 ± 0.310.07 ± 0.47
Usual Activities C21D220.14 ± 0.36—
Usual Activities C22D10.13 ± 0.520.08 ± 0.51
Usual Activities C22D220.36 ± 0.67—
Usual Activities C23D10.50 ± 0.630.00 ± 0.41
Usual Activities C23D220.18 ± 0.40—
Usual Activities C24D10.36 ± 0.63—
Usual Activities C25D10.17 ± 0.58—
Usual Activities C25D220.18 ± 0.40—
Usual Activities C26D10.15 ± 0.38—
Usual Activities C27D10.27 ± 0.47—
Usual Activities C28D10.17 ± 0.39—
Usual Activities 30 Day follow up0.29 ± 1.130.40 ± 1.02
Usual Activities 90 Day follow up0.41 ± 1.120.59 ± 1.06
Pain/Discomfort Baseline1.93 ± 0.871.98 ± 0.91
Pain/Discomfort C1D220.08 ± 0.93-0.15 ± 0.84
Pain/Discomfort C2D1-0.14 ± 0.91-0.36 ± 0.87
Pain/Discomfort C2D22-0.14 ± 0.88-0.24 ± 0.90
Pain/Discomfort C3D1-0.23 ± 0.94-0.31 ± 0.96
Pain/Discomfort C3D22-0.11 ± 0.88-0.31 ± 0.85
Pain/Discomfort C4D1-0.16 ± 0.93-0.28 ± 0.90
Pain/Discomfort C4D22-0.14 ± 0.89-0.28 ± 0.85
Pain/Discomfort C5D1-0.19 ± 0.88-0.22 ± 0.97
Pain/Discomfort C5D22-0.02 ± 1.04-0.19 ± 0.95
Pain/Discomfort C6D1-0.18 ± 0.87-0.19 ± 0.92
Pain/Discomfort C6D22-0.08 ± 0.96-0.26 ± 0.80
Pain/Discomfort C7D1-0.15 ± 0.91-0.21 ± 0.92
Pain/Discomfort C7D22-0.12 ± 0.97-0.30 ± 0.90
Pain/Discomfort C8D1-0.12 ± 0.91-0.18 ± 0.98
Pain/Discomfort C8D22-0.14 ± 0.88-0.34 ± 0.73
Pain/Discomfort C9D1-0.21 ± 1.02-0.29 ± 0.78
Pain/Discomfort C9D22-0.05 ± 0.80-0.31 ± 0.88
Pain/Discomfort C10D1-0.20 ± 0.95-0.30 ± 1.03
Pain/Discomfort C10D22-0.14 ± 0.88-0.35 ± 0.87
Pain/Discomfort C11D1-0.22 ± 0.89-0.17 ± 0.71
Pain/Discomfort C11D22-0.11 ± 0.83-0.32 ± 0.79
Pain/Discomfort C12D1-0.19 ± 0.81-0.15 ± 0.79
Pain/Discomfort C12D22-0.18 ± 0.95-0.27 ± 0.72
Pain/Discomfort C13D1-0.13 ± 0.89-0.20 ± 0.93
Pain/Discomfort C13D220.07 ± 0.93-0.19 ± 1.12
Pain/Discomfort C14D1-0.05 ± 0.83-0.33 ± 0.66
Pain/Discomfort C14D22-0.09 ± 0.89-0.47 ± 1.02
Pain/Discomfort C15D1-0.14 ± 0.73-0.07 ± 0.92
Pain/Discomfort C15D22-0.17 ± 0.83-0.35 ± 1.27
Pain/Discomfort C16D1-0.17 ± 0.71-0.14 ± 1.04
Pain/Discomfort C16D22-0.28 ± 0.80-0.29 ± 0.61
Pain/Discomfort C17D1-0.23 ± 0.73-0.33 ± 0.69
Pain/Discomfort C17D22-0.13 ± 0.92—
Pain/Discomfort C18D1-0.26 ± 0.900.00 ± 0.73
Pain/Discomfort C18D22-0.43 ± 0.81-0.20 ± 0.79
Pain/Discomfort C19D1-0.30 ± 0.70-0.07 ± 0.70
Pain/Discomfort C19D22-0.10 ± 0.72-0.18 ± 0.75
Pain/Discomfort C20D1-0.22 ± 0.800.00 ± 0.76
Pain/Discomfort C20D22-0.28 ± 0.750.10 ± 0.74
Pain/Discomfort C21D1-0.25 ± 0.64-0.14 ± 0.66
Pain/Discomfort C21D220.21 ± 0.58—
Pain/Discomfort C22D1-0.20 ± 0.68-0.17 ± 0.72
Pain/Discomfort C22D220.00 ± 0.77—
Pain/Discomfort C23D1-0.13 ± 0.89-0.23 ± 0.73
Pain/Discomfort C23D22-0.09 ± 0.83—
Pain/Discomfort C24D1-0.07 ± 1.14—
Pain/Discomfort C25D1-0.17 ± 0.72—
Pain/Discomfort C25D22-0.09 ± 0.70—
Pain/Discomfort C26D1-0.08 ± 0.76—
Pain/Discomfort C27D1-0.27 ± 0.79—
Pain/Discomfort C28D1-0.25 ± 0.97—
Pain/Discomfort 30 Day follow up-0.06 ± 0.960.17 ± 0.99
Pain/Discomfort 90 day follow up0.02 ± 1.040.07 ± 1.06
Anxiety/Depression Baseline1.76 ± 0.841.80 ± 0.83
Anxiety/Depression C1D22-0.03 ± 0.81-0.09 ± 0.70
Anxiety/Depression C2D1-0.09 ± 0.82-0.22 ± 0.73
Anxiety/Depression C2D22-0.09 ± 0.78-0.12 ± 0.78
Anxiety/Depression C3D1-0.14 ± 0.80-0.24 ± 0.76
Anxiety/Depression C3D22-0.10 ± 0.85-0.24 ± 0.80
Anxiety/Depression C4D1-0.22 ± 0.78-0.23 ± 0.84
Anxiety/Depression C4D22-0.10 ± 0.87-0.17 ± 0.88
Anxiety/Depression C5D1-0.15 ± 0.80-0.16 ± 0.81
Anxiety/Depression C5D22-0.11 ± 0.97-0.05 ± 0.79
Anxiety/Depression C6D1-0.20 ± 0.82-0.18 ± 0.86
Anxiety/Depression C6D22-0.08 ± 0.82-0.14 ± 0.94
Anxiety/Depression C7D1-0.12 ± 0.94-0.28 ± 0.77
Anxiety/Depression C7D22-0.06 ± 0.83-0.19 ± 0.77
Anxiety/Depression C8D1-0.18 ± 0.83-0.11 ± 0.86
Anxiety/Depression C8D22-0.10 ± 0.87-0.22 ± 0.80
Anxiety/Depression C9D1-0.17 ± 1.07-0.19 ± 0.83
Anxiety/Depression C9D22-0.08 ± 0.97-0.15 ± 0.87
Anxiety/Depression C10D1-0.17 ± 0.94-0.27 ± 0.88
Anxiety/Depression C10D22-0.16 ± 0.86-0.19 ± 0.96
Anxiety/Depression C11D1-0.21 ± 0.97-0.15 ± 0.89
Anxiety/Depression C11D22-0.20 ± 0.94-0.03 ± 1.17
Anxiety/Depression C12D1-0.09 ± 0.97-0.07 ± 0.93
Anxiety/Depression C12D22-0.11 ± 0.860.08 ± 0.98
Anxiety/Depression C13D1-0.10 ± 1.020.00 ± 1.08
Anxiety/Depression C13D22-0.10 ± 1.070.19 ± 0.98
Anxiety/Depression C14D1-0.03 ± 1.040.00 ± 1.11
Anxiety/Depression C14D22-0.19 ± 1.03-0.05 ± 1.13
Anxiety/Depression C15D1-0.26 ± 0.92-0.15 ± 0.86
Anxiety/Depression C15D22-0.17 ± 1.05-0.12 ± 0.99
Anxiety/Depression C16D1-0.29 ± 1.05-0.14 ± 0.99
Anxiety/Depression C16D22-0.41 ± 0.91-0.14 ± 0.66
Anxiety/Depression C17D1-0.10 ± 0.96-0.33 ± 0.69
Anxiety/Depression C17D22-0.26 ± 1.01—
Anxiety/Depression C18D1-0.48 ± 0.85-0.06 ± 0.93
Anxiety/Depression C18D22-0.33 ± 0.73-0.40 ± 0.97
Anxiety/Depression C19D1-0.30 ± 0.56-0.13 ± 0.74
Anxiety/Depression C19D22-0.25 ± 0.72-0.18 ± 1.08
Anxiety/Depression C20D1-0.26 ± 0.62-0.20 ± 0.77
Anxiety/Depression C20D22-0.39 ± 0.78-0.20 ± 0.79
Anxiety/Depression C21D1-0.35 ± 0.75-0.21 ± 0.89
Anxiety/Depression C21D22-0.36 ± 0.63—
Anxiety/Depression C22D1-0.27 ± 0.80-0.33 ± 0.78
Anxiety/Depression C22D220.00 ± 1.00—
Anxiety/Depression C23D1-0.06 ± 1.06-0.15 ± 0.69
Anxiety/Depression C23D22-0.18 ± 1.08—
Anxiety/Depression C24D10.00 ± 1.04—
Anxiety/Depression C25D1-0.17 ± 0.72—
Anxiety/Depression C25D22-0.27 ± 0.65—
Anxiety/Depression C26D1-0.23 ± 0.73—
Anxiety/Depression C27D1-0.27 ± 0.79—
Anxiety/Depression C28D1-0.33 ± 0.78—
Anxiety/Depression 30 Day follow up0.04 ± 1.010.12 ± 0.98
Anxiety/Depression 90 Day follow up0.01 ± 1.020.00 ± 0.96
Visual Analog Scale Baseline68.91 ± 19.1567.95 ± 19.78
Visual Analog Scale C1D22-3.44 ± 18.53-0.21 ± 15.63
Visual Analog Scale C2D10.05 ± 18.054.10 ± 17.43
Visual Analog Scale C2D220.63 ± 18.372.25 ± 19.26
Visual Analog Scale C3D11.16 ± 18.615.57 ± 18.23
Visual Analog Scale C3D22-1.69 ± 18.392.73 ± 19.27
Visual Analog Scale C4D10.35 ± 17.105.89 ± 17.65
Visual Analog Scale C4D22-1.11 ± 19.163.39 ± 17.41
Visual Analog Scale C5D1-0.54 ± 19.365.14 ± 17.26
Visual Analog Scale C5D220.37 ± 22.012.29 ± 18.00
Visual Analog Scale C6D11.28 ± 19.672.48 ± 20.43
Visual Analog Scale C6D224.33 ± 18.565.21 ± 16.71
Visual Analog Scale C7D11.32 ± 20.586.15 ± 15.20
Visual Analog Scale C7D223.51 ± 17.925.14 ± 14.60
Visual Analog Scale C8D13.77 ± 21.136.60 ± 14.65
Visual Analog Scale C8D222.71 ± 19.077.65 ± 14.13
Visual Analog Scale C9D15.05 ± 19.165.24 ± 13.63
Visual Analog Scale C9D222.44 ± 21.106.42 ± 15.96
Visual Analog Scale C10D12.52 ± 18.655.86 ± 18.29
C10D223.23 ± 17.276.72 ± 15.81
Visual Analog Scale C11D15.10 ± 17.237.33 ± 14.98
Visual Analog Scale C11D223.96 ± 15.635.58 ± 15.74
Visual Analog Scale C12D11.06 ± 18.033.95 ± 17.66
Visual Analog Scale C12D22-1.55 ± 17.563.69 ± 16.11
Visual Analog Scale C13D13.27 ± 17.643.34 ± 17.40
Visual Analog Scale C13D22-0.29 ± 18.301.67 ± 17.02
Visual Analog Scale C14D1-0.15 ± 16.815.83 ± 13.93
Visual Analog Scale C14D22-0.25 ± 18.753.53 ± 14.98
Visual Analog Scale C15D1-0.09 ± 16.907.11 ± 14.91
Visual Analog Scale C15D22-2.63 ± 23.872.29 ± 17.85
Visual Analog Scale C16D12.43 ± 16.373.86 ± 15.94
Visual Analog Scale C16D222.00 ± 15.260.36 ± 12.34
Visual Analog Scale C17D12.50 ± 16.741.72 ± 14.90
Visual Analog Scale C17D22-2.61 ± 17.26—
Visual Analog Scale C18D12.85 ± 18.612.69 ± 12.72
Visual Analog Scale C18D220.86 ± 18.742.90 ± 12.08
Visual Analog Scale C19D15.39 ± 16.573.33 ± 14.11
Visual Analog Scale C19D22-0.25 ± 19.053.73 ± 10.36
Visual Analog Scale C20D11.57 ± 21.463.67 ± 13.97
Visual Analog Scale C20D220.78 ± 16.007.00 ± 14.24
Visual Analog Scale C21D12.80 ± 15.834.00 ± 15.06
Visual Analog Scale C21D22-4.64 ± 12.29—
Visual Analog Scale C22D11.33 ± 17.374.25 ± 16.19
Visual Analog Scale C22D22-6.00 ± 19.20—
Visual Analog Scale C23D1-2.25 ± 18.365.31 ± 17.77
Visual Analog Scale C23D22-3.09 ± 16.57—
Visual Analog Scale C24D1-3.43 ± 18.81—
Visual Analog Scale C25D1-4.08 ± 15.32—
Visual Analog Scale C25D22-4.64 ± 14.43—
Visual Analog Scale C26D11.69 ± 16.79—
Visual Analog Scale C27D11.45 ± 17.15—
Visual Analog Scale C28D1-0.42 ± 17.61—
Visual Analog Scale 30 Day follow up-1.33 ± 18.53-2.07 ± 17.67
Visual Analog Scale 90 Day follow up-3.79 ± 20.59-4.84 ± 19.73
SecondaryPharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)

Ctrough was defined as the predose concentration at the end of dosing interval.

Time frame:
Predose on C1D22, C3D1, C5D1, C7D1, C9D1
Reported as:
Mean · micrograms/mililiter (ug/mL)
Pharmacokinetics (PK) of Zolbetuximab in Serum: Trough Concentration (Ctrough)
micrograms/mililiter (ug/mL)mFOLFOX6 + Zolbetuximab
C1D2240.9 ± 37.2
C3D170.1 ± 49.8
C5D197.4 ± 50.8
C7D1118.0 ± 64.9
C9D1135.0 ± 56.2
SecondaryNumber of Participants With Anti-drug Antibodies (ADA)

Immunogenicity will be measured by the number of participants that are ADA positive.

Time frame:
Predose on C1D1, C1D22, C3D1, C5D1, C7D1, C9D1, 30-day follow up, 90-day follow up
Reported as:
Number · Participants
Number of Participants With Anti-drug Antibodies (ADA)
ParticipantsmFOLFOX6 + Zolbetuximab
C1D12
C1D222
C3D13
C5D12
C7D12
C9D11
30 day follow up4
90 day follow up1

Adverse events

Collected over All- cause mortality (ACM): From randomization up to 62 months and 18 days Adverse events: From first dose until 62 months and 18 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zolbetuximab197/283 (69.6%)133/279 (47.7%)276/279 (98.9%)
5-fluorouracil414/565 (73.3%)262/557 (47%)550/557 (98.7%)
Folinic Acid / Leucovorin414/565 (73.3%)262/557 (47%)550/557 (98.7%)
Oxaliplatin414/565 (73.3%)262/557 (47%)550/557 (98.7%)
Placebo217/282 (77%)129/278 (46.4%)274/278 (98.6%)
Most frequent serious events
Showing 10 of 221
Most frequent serious events
EventZolbetuximab5-fluorouracilFolinic Acid / LeucovorinOxaliplatinPlacebo
VomitingGastrointestinal disorders24/27938/55738/55738/55714/278
NauseaGastrointestinal disorders19/27931/55731/55731/55712/278
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/27922/55722/55722/55712/278
Abdominal painGastrointestinal disorders5/27914/55714/55714/5579/278
PneumoniaInfections and infestations7/27915/55715/55715/5578/278
Febrile neutropeniaBlood and lymphatic system disorders8/2799/5579/5579/5571/278
DiarrhoeaGastrointestinal disorders8/27913/55713/55713/5575/278
Intestinal obstructionGastrointestinal disorders7/27912/55712/55712/5575/278
PyrexiaGeneral disorders7/27913/55713/55713/5576/278
General physical health deteriorationGeneral disorders2/2798/5578/5578/5576/278
Most frequent other events
Showing 10 of 65
Most frequent other events
EventZolbetuximab5-fluorouracilFolinic Acid / LeucovorinOxaliplatinPlacebo
NauseaGastrointestinal disorders226/279396/557396/557396/557170/278
VomitingGastrointestinal disorders180/279278/557278/557278/55798/278
Decreased appetiteMetabolism and nutrition disorders136/279233/557233/557233/55797/278
DiarrhoeaGastrointestinal disorders112/279237/557237/557237/557125/278
Peripheral sensory neuropathyNervous system disorders107/279226/557226/557226/557119/278
ConstipationGastrointestinal disorders101/279212/557212/557212/557111/278
AnaemiaBlood and lymphatic system disorders105/279211/557211/557211/557106/278
NeutropeniaBlood and lymphatic system disorders101/279195/557195/557195/55794/278
Neutrophil count decreasedInvestigations96/279185/557185/557185/55789/278
FatigueGeneral disorders83/279175/557175/557175/55792/278

Baseline characteristics

Full analysis set(FAS) included all participants who were randomized to 1 of the treatment arms.

Age, Continuous
Age, Continuous(Years)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
Mean59.7 ± 11.758.8 ± 13.059.3 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
Female107107214
Male176175351
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
Hispanic or Latino363773
Not Hispanic or Latino225213438
Unknown or Not Reported223254
Race (NIH/OMB)
Race (NIH/OMB)(Participants)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
American Indian or Alaska Native9817
Asian9697193
Native Hawaiian or Other Pacific Islander000
Black or African American527
White140134274
More than one race000
Unknown or Not Reported334174
Region (Asia vs Non-Asia)
Region (Asia vs Non-Asia)(Participants)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
Asia8889177
Non- Asia195193388
Number of organs with metastatic sites
Number of organs with metastatic sites(Participants)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
0-2 metastatic sites219219438
>=3 metastatic sites6463127
Prior Gastrectomy
Prior Gastrectomy(Participants)mFOLFOX6 + ZolbetuximabmFOLFOX6+PlaceboTotal
YES8482166
NO199200399
08

Study locations

218 sites
  • University of Arizona
    Phoenix, Arizona 85004, United States
  • The University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer
    Bakersfield, California 93309, United States
  • City of Hope Nat'l Medical Center
    Duarte, California 91010, United States
  • St. Jude Hospital Yorba Linda
    Fullerton, California 92835, United States
  • Pacific Shores Medical Group
    Huntington Beach, California 92648, United States
  • Loma Linda University
    Loma Linda, California 92354, United States
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • University of California Davis
    Sacramento, California 95817, United States
  • University of California - San Francisco
    San Francisco, California 94143, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Memorial Sloan Kettering Cancer Center
    Middletown, Connecticut 07748-3052, United States
  • Memorial Cancer Institute - West
    Hollywood, Florida 33021, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Orlando Health Inc
    Orlando, Florida 32806, United States
  • Memorial Hospital West
    Pembroke Pines, Florida 33028, United States
  • Cancer Treatment Centers of America, Atlanta
    Newnan, Georgia 30265, United States
  • Northwestern University Medical Center
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40217, United States
  • University of Maryland Medical Center(UMMC)Transplant Center
    Baltimore, Maryland 21201, United States
  • Maryland Oncology Hematology
    Brandywine, Maryland 20613, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2696, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Health Partners Institute
    Saint Louis Park, Minnesota 55426, United States
  • Regions Hospital
    Saint Paul, Minnesota 55101, United States
  • Memorial Sloan Kettering Cancer Center
    Basking Ridge, New Jersey 07920, United States
  • Memorial Sloan Kettering Cancer Center
    Montvale, New Jersey 07645, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center
    Harrison, New York 10604, United States
  • Mount Sinai School of Medicine
    New York, New York 10029-6574, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794-9452, United States
  • Memorial Sloan Kettering Cancer Center
    Uniondale, New York 11553, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Precision Cancer Research -Dayton Physicians Network
    Middletown, Ohio 45042, United States
  • University of Oklahoma Health Science Center
    Oklahoma City, Oklahoma 73104, United States
  • Earle A. Chiles Research Institute
    Portland, Oregon 97213, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17604, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Cancer Treatment Centers of America, Philadelphia
    Philadelphia, Pennsylvania 19124, United States
  • Rhode Island Hospital-Lifespan Cancer Institute
    Providence, Rhode Island 02903, United States
  • Sanford Cancer Center
    Sioux Falls, South Dakota 57104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Inova Dwight and Martha Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • MultiCare Regional Cancer Center - Gig Harbor
    Auburn, Washington 98801, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Site AU61002
    Douglas, Queensland 4814, Australia
  • Site AU61011
    Tugun, Queensland 4224, Australia
  • Site AU61008
    Adelaide, South Australia 5011, Australia
  • Site AU61006
    East Bentleigh, Victoria 3165, Australia
  • Site AU61007
    Kogarah, 2217, Australia
  • Site BE32007
    Edegem, Antwerpen 2650, Belgium
  • Site BE32001
    Brussels, Bruxelles-Capitale, Région de 1200, Belgium
  • Site BE32008
    Mons, Hainaut 7000, Belgium
  • Site BE32002
    Brussels, Liege 1050, Belgium
  • Site BE32012
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Site BE32006
    Leuven, Vlaams Brabant 3000, Belgium
  • Site BE32005
    Bruges, 8310, Belgium
  • Site BE32004
    Brussels, 1000, Belgium
  • Site BE32011
    Charleroi, 6000, Belgium
  • Site BE32010
    Haine-Saint-Paul, 7100, Belgium
  • Site BR55010
    Brasília, Federal District 70200-730, Brazil
  • Site BR55006
    Lajeado, Rio Grande do Sul 95900000, Brazil
  • Site BR55002
    Itajaí, Santa Catarina 88301-220, Brazil
  • Site BR55007
    Barretos, São Paulo 14784-400, Brazil
  • Site BR55003
    Santo André, São Paulo 09060-650, Brazil
  • Site BR55005
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Site BR55017
    Belo Horizonte, 30130-090, Brazil
  • Site BR55016
    Passo Fundo, 99010-260, Brazil
  • Site BR55015
    Rio de Janeiro, 22793-080, Brazil
  • Site BR55018
    Santa Catarina, 88501-003, Brazil
  • Site BR55009
    São Paulo, 01509-900, Brazil
  • Site BR55004
    São Paulo, 08270-070, Brazil
  • Site CA15005
    Edmonton, Alberta T6G 1Z2, Canada
  • Site CA15009
    Saint John, New Brunswick E2L 4L4, Canada
  • Site CA15011
    Toronto, Ontario M5G 1X5, Canada
  • Site CA15002
    Montreal, Quebec H3T 1M5, Canada
  • Site CA15008
    Montreal, Quebec H4A 3J1, Canada
  • Site CL56003
    Providencia, Santiago Metropolitan 7500921, Chile
  • Site CL56008
    Providencia, 7520378, Chile
  • Site CL56005
    Santiago, 8330032, Chile
  • Site CL56007
    Valdivia, 5090000, Chile
  • Site CN86003
    Haerbin, Heilongjiang 150081, China
  • Site CN86006
    Nanjing, Jiangsu 210008, China
  • Site CN86004
    Hangzhou, Zhejiang 310003, China
  • Site CN86009
    Beijing, 100030, China
  • Site CN86005
    Hefei, 230022, China
  • Site CN86001
    Xiamen, China
  • Site CN86008
    Zhengzhou, 450000, China
  • Site CO57006
    Medellín, Antioquia 574, Colombia
  • Site CO57009
    Bogotá, DC 110231, Colombia
  • Site CO57007
    Montería, Departamento de Córdoba 230002, Colombia
  • Site CO57005
    Cali, Valle del Cauca Department, Colombia
  • Site CO57001
    Cali, Colombia
  • Site CO57002
    Medellín, 0574, Colombia

Showing the first 100 of 218 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yamaguchi K, Shoji H, Yasui H, Oki E, Sakai D, Hamaguchi T, Tsuji A, Oshima T, Tsuda M, Minashi K, Yang J, Guerrero A, Ueno Y, Matsangou M, Gourgioti G, Nakanishi Y, Furuki S, Kuwamoto K, Yamada S, Shitara K. Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials. Gastric Cancer. 2026 Jul;29(4):777-787. doi: 10.1007/s10120-026-01738-7. Epub 2026 May 7. PubMed 42095986 ↗
  • Stratton SP, Pang L, Pugh J, Kouzova M, Baldwin D, McDonald J, Lawrence-Glaze R, Moran S, Guerrero A, Moran D. Analytical and Clinical Performance of the VENTANA CLDN18 (43-14A) RxDx Assay in Gastric and Gastroesophageal Junction Adenocarcinoma Tissue Samples in SPOTLIGHT and GLOW. Mod Pathol. 2025 Dec;38(12):100844. doi: 10.1016/j.modpat.2025.100844. Epub 2025 Jul 16. PubMed 40680855 ↗
  • Shitara K, Shah MA, Lordick F, Bang YJ, Ilson D, Van Cutsem E, Enzinger P, Kim SS, Klempner SJ, Moran D, Park JW, Bhattacharya P, Ajani JA, Xu RH. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary. Future Oncol. 2024;20(26):1861-1877. doi: 10.1080/14796694.2024.2342107. Epub 2024 May 24. PubMed 38861294 ↗
  • Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. PubMed 37068504 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Sep 2022, 50 months.

Results were first posted in Feb 2025, 2 years 5 months after primary completion. A results delay was requested in Sep 2023.

Of 26 phase 3 interventional studies under Adenocarcinoma, half reached primary completion within 91 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 101. This study's 50 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2018
First posted
Apr 20, 2018
StartActual
Jun 21, 2018
Primary completionActual
Sep 9, 2022
CompletionEst.
Mar 31, 2027was Sep 2026
Results delay requested
Sep 7, 2023
Results first posted
Feb 26, 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites removed
Show 2 removed
  • Site CN86002 · Beijing, China
  • Site MX52004 · Oaxaca City, Mexico
Oct 20, 2026
Study completion
Sep 30, 2026→Mar 31, 2027
Oct 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40680855 ↗
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40680855 ↗
    2 sites removed
    Show 2 removed
    • Site CN86002 · Beijing, China
    • Site MX52004 · Oaxaca City, Mexico
    Study completion Sep 30, 2026→Mar 31, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03504397
Responsible party
Sponsor
First posted
Apr 20, 2018
Start date
Jun 21, 2018
Primary completion
Sep 9, 2022
Completion
Mar 31, 2027 (estimated)
Results posted
Feb 26, 2025
Last update
Oct 20, 2026

Study contacts

Global Medical Lead
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion